

# Comparative analysis of the risks of hospitalisation and omicron (B.1.1.529) and delta (B.1.617.2) variants in Engla

Lancet, The

399, 1303-1312

DOI: [10.1016/s0140-6736\(22\)00462-7](https://doi.org/10.1016/s0140-6736(22)00462-7)

Citation Report

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 5  | Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. <i>Journal of Infectious Diseases</i> , 2022, 226, 808-811.           | 4.0  | 7         |
| 9  | Omicron: fewer adverse outcomes come with new dangers. <i>Lancet</i> , The, 2022, 399, 1280-1281.   | 13.7 | 17        |
| 10 | Impact of implementation timing on the effectiveness of stay-at-home requirement under the COVID-19 pandemic: Lessons from the Italian Case. <i>Health Policy</i> , 2022, 126, 504-511.                             | 3.0  | 2         |
| 12 | An assessment of the potential impact of the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. <i>Infectious Disease Modelling</i> , 2022, 7, 94-105.  | 1.9  | 12        |
| 13 | Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19. <i>Open Forum Infectious Diseases</i> , 2022, 9, .   | 0.9  | 11        |
| 15 | Seasonality of COVID-19 deaths. Did social restrictions and vaccination actually impact the official reported dynamic of COVID-19 pandemic in Italy?. <i>Environmental Research</i> , 2022, 212, 113229.            | 7.5  | 4         |
| 16 | Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China*. <i>Emerging Microbes and Infections</i> , 2022, 11, 1205-1214.                                    | 6.5  | 5         |
| 17 | Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave. <i>Clinical Infectious Diseases</i> , 2022, 75, 2193-2200. | 5.8  | 40        |
| 19 | Intrinsic Severity of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1867-1868.  | 27.0 | 3         |
| 20 | Omicron XE emerges as SARS-CoV-2 keeps evolving. <i>Innovation(China)</i> , 2022, 3, 100248.  | 9.1  | 13        |
| 21 | COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge. <i>Cancer Cell</i> , 2022, 40, 578-580.  | 16.8 | 12        |
| 22 | Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. <i>Eurosurveillance</i> , 2022, 27, .        | 7.0  | 26        |
| 23 | Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e37377.   | 2.6  | 2         |
| 24 | Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 366.e1-366.e7.         | 1.2  | 10        |
| 25 | Exploring the Utility of NK Cells in COVID-19. <i>Biomedicines</i> , 2022, 10, 1002.  | 3.2  | 12        |
| 26 | A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. <i>PLoS Pathogens</i> , 2022, 18, e1010465.                  | 4.7  | 8         |
| 27 | Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. <i>Nature Reviews Immunology</i> , 2022, 22, 387-397.  | 22.7 | 93        |
| 32 | Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. <i>MedComm</i> , 2022, 3, e143.  | 7.2  | 3         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 33 | Pathogenicity of SARS-CoV-2 Omicron. <i>Clinical and Translational Medicine</i> , 2022, 12, e880.   | 4.0  | 12        |
| 34 | Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, .  | 2.6  | 39        |
| 35 | Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. <i>Gut</i> , 2023, 72, 410-412.  | 12.1 | 5         |
| 36 | Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters. <i>EBioMedicine</i> , 2022, 80, 104035.   | 6.1  | 4         |
| 37 | Molecular Analysis of SARS-CoV-2 Lineages in Armenia. <i>Viruses</i> , 2022, 14, 1074.  | 3.3  | 7         |
| 38 | BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. <i>Nature Microbiology</i> , 2022, 7, 909-917.   | 13.3 | 41        |
| 39 | Maske rauf, Maske runter. <i>Hautnah</i> , 2022, 21, 64-65.   | 0.0  | 0         |
| 40 | Excess total mortality during the Covid-19 pandemic in Italy: updated estimates indicate persistent excess in recent months.. <i>Medicina Del Lavoro</i> , 2022, 113, e2022021.   | 0.4  | 10        |
| 41 | SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!. <i>Acta Biomedica</i> , 2022, 93, e2022097.   | 0.3  | 1         |
| 42 | mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022. <i>Eurosurveillance</i> , 2022, 27, . | 7.0  | 2         |
| 43 | Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022. <i>Eurosurveillance</i> , 2022, 27, .   | 7.0  | 18        |
| 45 | Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. <i>Science</i> , 2022, 376, .  | 12.6 | 78        |
| 47 | SARS-CoV-2 Antibody Prevalence in Adult Patients with Short Bowel Syndrome – A German Multicenter Cross-sectional Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 0, , .  | 2.6  | 1         |
| 48 | Transforming or tinkering: the world remains unprepared for the next pandemic threat. <i>Lancet</i> , The, 2022, 399, 1995-1999.  | 13.7 | 12        |
| 49 | Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study. <i>EClinicalMedicine</i> , 2022, 48, 101455.                        | 7.1  | 49        |
| 50 | Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. <i>The Lancet Global Health</i> , 2022, 10, e961-e969.   | 6.3  | 120       |
| 51 | Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021–February 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 1355-1365.  | 4.3  | 18        |
| 52 | Estimation of the Seroprevalence and Infection Fatality Rate of the SARS-CoV-2 Omicron Variant Using Antibody Screening of Danish Blood Donors. <i>SSRN Electronic Journal</i> , 0, , .   | 0.4  | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 53 | Omicron Infection Induces Low-Level, Narrow-Range SARS-CoV-2 Neutralizing Activity. SSRN Electronic Journal, 0, , .  | 0.4  | 1         |
| 54 | The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity, 2022, 55, 1316-1326.e4.   | 14.3 | 38        |
| 56 | Thromboprophylaxis and anticoagulation for inpatients with coronavirus disease 2019 in 2022 and beyond. Clinical Microbiology and Infection, 2022, , .   | 6.0  | 0         |
| 59 | Leveraging South African <sc>HIV</sc> research to define <sc>SARSâ€CoV</sc>â€2 immunity triggered by sequential variants of concern. Immunological Reviews, 2022, 310, 61-75.  | 6.0  | 6         |
| 61 | Has the Game Come to an End?. Wetchasan Songkla Nakarin, 2022, 2, 43.  | 0.1  | 0         |
| 62 | Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice. Viruses, 2022, 14, 1139.  | 3.3  | 21        |
| 64 | Recent insights into SARSâ€CoVâ€2 omicron variant. Reviews in Medical Virology, 2023, 33, .  | 8.3  | 29        |
| 66 | SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Eurosurveillance, 2022, 27, .   | 7.0  | 51        |
| 67 | A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2. Frontiers in Microbiology, 2022, 13, .  | 3.5  | 10        |
| 68 | Demographics and Outcomes of COVID-19 Medicines Delivery Units Across 4 UK Centres During the Initial B.1.1.529 Omicron Epidemic: A Service Evaluation.. SSRN Electronic Journal, 0, , .   | 0.4  | 2         |
| 69 | RT-RPA-Cas12a-Based Discrimination of SARS-CoV-2 Variants of Concern. SSRN Electronic Journal, 0, , .  | 0.4  | 0         |
| 70 | The Effects of Vaccination on the Diseaseâ€Severityâ€And Factors for Viral Clearanceâ€And Hospitalization in Omicron-Infectedâ€Patientsi74šâ€Retrospective Observational Cohort Study from Recent Regional Outbreaks in China. SSRN Electronic Journal, 0, , .   | 0.4  | 0         |
| 73 | Is Ivermectin Effective in Treating COVID-19?. Frontiers in Pharmacology, 0, 13, .   | 3.5  | 3         |
| 74 | The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .   | 2.8  | 24        |
| 76 | Outcome of infection with omicron <sc>SARSâ€CoV</sc>â€2 variant in patients with hematological malignancies: An <sc>EPICOVIDEHA</sc> survey report. American Journal of Hematology, 2022, 97, .  | 4.1  | 39        |
| 77 | Addressing COVID-19 vaccine hesitancy. Drugs in Context, 0, 11, 1-19.  | 2.2  | 11        |
| 78 | Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. The Lancet Regional Health Americas, 2022, 12, 100297. | 2.6  | 37        |
| 80 | Effect of COVID-19 Vaccination Campaign in Belgian Nursing Homes on COVID-19 Cases, Hospital Admissions, and Deaths among Residents. Viruses, 2022, 14, 1359.  | 3.3  | 4         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 81  | Assessing Vaccination Prioritization Strategies for COVID-19 in South Africa Based on Age-Specific Compartment Model. <i>Frontiers in Public Health</i> , 0, 10, .  | 2.7  | 12        |
| 83  | Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients. <i>Frontiers in Immunology</i> , 0, 13, .                                     | 4.8  | 18        |
| 84  | Immunological memory to <scp>SARS-CoV-2</scp> infection and <scp>COVID-19</scp> vaccines. <i>Immunological Reviews</i> , 2022, 310, 27-46.  | 6.0  | 137       |
| 85  | Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant. <i>Vaccines</i> , 2022, 10, 986.  | 4.4  | 7         |
| 89  | Decreased Risk of COVID-19-Related Hospitalization Associated with Omicron Variant of SARS-CoV-2. <i>Open Forum Infectious Diseases</i> , 0, , .  | 0.9  | 6         |
| 90  | Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.   | 3.3  | 30        |
| 93  | The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. <i>Frontiers in Medicine</i> , 0, 9, .                         | 2.6  | 2         |
| 94  | Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. <i>Emerging Microbes and Infections</i> , 2022, 11, 1742-1750. | 6.5  | 43        |
| 95  | Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications. <i>Journal of Clinical Practice</i> , 2022, 13, 66-87.  | 0.6  | 1         |
| 97  | Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. <i>Nature Medicine</i> , 2022, 28, 1933-1943.               | 30.7 | 243       |
| 98  | Surveillance of omicron variants through wastewater epidemiology: Latest developments in environmental monitoring of pandemic. <i>Science of the Total Environment</i> , 2022, 843, 156724.               | 8.0  | 6         |
| 99  | Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021â€“2022. <i>Viruses</i> , 2022, 14, 1297.         | 3.3  | 41        |
| 100 | Monitoring the COVID-19 immune landscape in Japan. <i>International Journal of Infectious Diseases</i> , 2022, 122, 300-306.  | 3.3  | 5         |
| 101 | Pregnancy Outcomes Following Delta and Omicron SARS-CoV-2 Infection in Scotland: A Population-Based Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .   | 0.4  | 0         |
| 102 | Photoluminescent Inorganic Nanoprobeâ€“Based Pathogen Detection. <i>Chemistry - an Asian Journal</i> , 2022, 17, .  | 3.3  | 2         |
| 105 | COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. <i>Nature Communications</i> , 2022, 13, .  | 12.8 | 29        |
| 108 | Clinical outcomes of the omicron variant compared with previous SARS-CoV-2 variants; meta-analysis of current reports. <i>World Journal of Meta-analysis</i> , 2022, 10, 177-185.                         | 0.1  | 0         |
| 109 | Case Report: The Experience of Managing a Moderate ARDS Caused by SARS-CoV-2 Omicron BA.2 Variant in Chongqing, China: Can We Do Better?. <i>Frontiers in Medicine</i> , 0, 9, .                          | 2.6  | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 110 | The COVID-19 Vaccination Still Matters: Omicron Variant Is a Final Wake-Up Call for the Rich to Help the Poor. <i>Vaccines</i> , 2022, 10, 1070.  | 4.4  | 10        |
| 111 | Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 0, 11, .  | 6.0  | 7         |
| 112 | Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5â€“11 years in Italy: a retrospective analysis of Januaryâ€“April, 2022. <i>Lancet, The</i> , 2022, 400, 97-103.           | 13.7 | 78        |
| 113 | SARS-CoV-2 Antibody Response against Mild-to-Moderate Breakthrough COVID-19 in Home Isolation Setting in Thailand. <i>Vaccines</i> , 2022, 10, 1131.  | 4.4  | 3         |
| 115 | Viral load of SARSâ€“CoVâ€“2 Omicron is not high despite its high infectivity. <i>Journal of Medical Virology</i> , 2022, 94, 5543-5546.  | 5.0  | 22        |
| 116 | Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark. <i>American Journal of Transplantation</i> , 2022, 22, 2637-2650.           | 4.7  | 22        |
| 117 | SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production. <i>IScience</i> , 2022, 25, 104759.  | 4.1  | 11        |
| 119 | Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1435-1443.               | 9.1  | 233       |
| 120 | Monoclonals for patients hospitalised with COVID-19. <i>Lancet Respiratory Medicine, the</i> , 2022, 10, 928-930.   | 10.7 | 3         |
| 121 | New SARS-CoV-2 Omicron variant â€” clinical picture, treatment, prevention (literature review). <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 21, 3228.   | 1.4  | 9         |
| 123 | A More Accurate Measurement of the Burden of Coronavirus Disease 2019 Hospitalizations. <i>Open Forum Infectious Diseases</i> , 2022, 9, .  | 0.9  | 4         |
| 124 | Rapid displacement of SARS-CoV-2 variant Delta by Omicron revealed by allele-specific PCR in wastewater. <i>Water Research</i> , 2022, 221, 118809.   | 11.3 | 30        |
| 125 | A severe presentation of breakthrough infection caused by the Omicron variant with radiological findings of COVID-19 pneumonia in an elderly woman. <i>Radiology Case Reports</i> , 2022, 17, 3326-3330.                        | 0.6  | 2         |
| 126 | Nirmatrelvir for Nonhospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2022, 387, 474-476.   | 27.0 | 5         |
| 127 | An Overview of Neurological and Psychiatric Complications During Post-COVID Period: A Narrative Review. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4199-4215.  | 3.5  | 4         |
| 128 | Finite neutralisation breadth of omicron after repeated vaccination. <i>Lancet Microbe, The</i> , 2022, 3, e729.  | 7.3  | 3         |
| 129 | Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e172-e178. | 5.8  | 54        |
| 130 | A Case Report of Breakthrough Infections With 2 SARS-CoV-2 Variants in a Lung Transplant Patient. <i>Transplantation Proceedings</i> , 2022, 54, 2698-2701.   | 0.6  | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 132 | Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study. <i>SSRN Electronic Journal</i> , 0, , .   | 0.4  | 17        |
| 133 | Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2 Omicron variant BA.1 infection of human airway epithelial organoids. <i>Current Research in Microbial Sciences</i> , 2022, 3, 100158.   | 2.3  | 4         |
| 134 | Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1 <sup>st</sup> –August 20, 2021): a retrospective observational monocentric study. <i>BMC Infectious Diseases</i> , 2022, 22, . | 2.9  | 2         |
| 135 | Risk Perception, Media, and Ordinary People <sup>TM</sup> s Intention to Engage in Self-Protective Behaviors in the Early Stage of COVID-19 Pandemic in China. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 1459-1471.  | 2.5  | 4         |
| 136 | Analysis of multi-strain infection of vaccinated and recovered population through epidemic model: Application to COVID-19. <i>PLoS ONE</i> , 2022, 17, e0271446.  | 2.5  | 2         |
| 138 | Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency. <i>Frontiers in Immunology</i> , 0, 13, .  | 4.8  | 11        |
| 139 | Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.   | 3.3  | 27        |
| 140 | Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1816-1828.   | 2.9  | 9         |
| 141 | Epidemiological Comparison of Four COVID-19 Waves in the Democratic Republic of the Congo, March 2020–January 2022. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 316-327.   | 2.9  | 13        |
| 142 | COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). <i>ELife</i> , 0, 11, .   | 6.0  | 36        |
| 143 | Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. <i>Nature Communications</i> , 2022, 13, .   | 12.8 | 34        |
| 144 | SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. <i>Lancet Rheumatology</i> , The, 2022, 4, e747-e750.   | 3.9  | 10        |
| 145 | COVID-19 Hospitalization Among Children &lt;18 Years by Variant Wave in Norway. <i>Pediatrics</i> , 2022, 150, .  | 2.1  | 23        |
| 147 | Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 <sup>st</sup> –284 <sup>th</sup> –437 patients. <i>Lancet Psychiatry</i> , the, 2022, 9, 815-827.   | 7.4  | 305       |
| 149 | Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. <i>Frontiers in Immunology</i> , 0, 13, .   | 4.8  | 32        |
| 151 | Infection with the Omicron variant of SARS-CoV-2 is associated with less severe disease in hospitalized patients with COVID-19. <i>Journal of Infection</i> , 2022, 85, e152-e154.  | 3.3  | 10        |
| 153 | Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis. <i>Biochip Journal</i> , 2022, 16, 376-396.  | 4.9  | 20        |
| 154 | Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. <i>Clinical Infectious Diseases</i> , 0, , .   | 5.8  | 43        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 155 | CLL and COVID-19: light at the end of the tunnel?. <i>Blood</i> , 2022, 140, 407-409.  | 1.4  | 3         |
| 157 | The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, .  | 3.4  | 35        |
| 158 | Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignanciesâ€”The First Single-Centre Experience from the Czech Republic. <i>Life</i> , 2022, 12, 1184.  | 2.4  | 1         |
| 160 | Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. <i>JAMA Network Open</i> , 2022, 5, e2228900.   | 5.9  | 42        |
| 161 | Transmissibility, hospitalization, and intensive care admissions due to omicron compared to delta variants of SARS-CoV-2 in Catalonia: A cohort study and ecological analysis. <i>Frontiers in Public Health</i> , 0, 10, .  | 2.7  | 11        |
| 163 | Evolution of throat symptoms during the COVID-19 pandemic in the US. <i>Diagnosis</i> , 2022, .  | 1.9  | 4         |
| 164 | Editorial Commentary on â€œSeverity of Illness Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern in Children: A Single-Center Retrospective Cohort Studyâ€. <i>Journal of the Pediatric Infectious Diseases Society</i> , 0, , .                    | 1.3  | 0         |
| 166 | Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study. <i>Clinical Microbiology and Infection</i> , 2023, 29, 101-106.  | 6.0  | 16        |
| 167 | Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO). <i>Med</i> , 2022, 3, 531-537.  | 4.4  | 2         |
| 168 | Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. <i>BMJ, The</i> , 0, , e070695.  | 6.0  | 98        |
| 169 | Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1742-1749.  | 0.9  | 26        |
| 170 | Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period. <i>Frontiers in Immunology</i> , 0, 13, . | 4.8  | 12        |
| 171 | Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus. <i>Microorganisms</i> , 2022, 10, 1688.  | 3.6  | 2         |
| 172 | The second year of pandemic in the Arctic: examining spatiotemporal dynamics of the COVID-19 â€œDelta waveâ€ in Arctic regions in 2021. <i>International Journal of Circumpolar Health</i> , 2022, 81, .  | 1.2  | 10        |
| 173 | Dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 in England. <i>Nature Communications</i> , 2022, 13, .  | 12.8 | 22        |
| 174 | Covid-19: is omicron less lethal than delta?. <i>BMJ, The</i> , 0, , o1806.  | 6.0  | 20        |
| 176 | Outcomes of Solid Organ Transplant Recipients Treated With Antispike Monoclonal Antibodies for Coronavirus Disease 2019 Across Variant Epochs: Impact of Comorbidities and Vaccination. <i>Transplantation</i> , 2022, 106, e507-e509.   | 1.0  | 6         |
| 177 | The Race for Global Equitable Access to COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1306.   | 4.4  | 26        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 178 | A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113499.  | 5.6  | 12        |
| 179 | Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, Januaryâ€“March 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 1856-1858.  | 4.3  | 86        |
| 180 | Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning. <i>Computers in Biology and Medicine</i> , 2022, 149, 105969.  | 7.0  | 7         |
| 181 | Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. <i>Lancet Regional Health - Europe</i> , The, 2022, 21, 100479.                       | 5.6  | 29        |
| 182 | Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.                      | 5.6  | 56        |
| 184 | Excess Mortality among Physicians and Dentists during COVID-19 in Italy: A Cross-Sectional Study Related to a High-Risk Territory. <i>Healthcare (Switzerland)</i> , 2022, 10, 1684.                                | 2.0  | 4         |
| 185 | Role of Demyelination in the Persistence of Neurological and Mental Impairments after COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11291.   | 4.1  | 10        |
| 187 | Laboratory markers of severity across three COVID-19 outbreaks in Australia: has Omicron and vaccinations changed disease presentation?. <i>Internal and Emergency Medicine</i> , 2023, 18, 43-52.                  | 2.0  | 8         |
| 189 | Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e727-e737. | 12.3 | 15        |
| 190 | SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA. <i>Emerging Infectious Diseases</i> , 2022, 28, .   | 4.3  | 7         |
| 191 | Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?. <i>International Journal of Infectious Diseases</i> , 2022, 124, 1-10.                                  | 3.3  | 12        |
| 192 | Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .                      | 0.4  | 3         |
| 193 | Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2. <i>Immune Network</i> , 2022, 22, .   | 3.6  | 12        |
| 194 | The Problem of Home Therapy during COVID-19 Pandemic in Italy: Government Guidelines versus Freedom of Cure?. <i>Journal of Pharmacy and Pharmacology Research</i> , 2022, 06, .                                    | 0.3  | 2         |
| 195 | Optimizing Symptom Based Testing Strategies for Pandemic Mitigation. <i>IEEE Access</i> , 2022, 10, 84934-84945.  | 4.2  | 4         |
| 196 | COVID-19 Vaccine Protection Against Mortality in Hospitalized Patients with Oxygen Requirement: A Multicontinental Retrospective Study. <i>SSRN Electronic Journal</i> , 0, , .                                     | 0.4  | 1         |
| 197 | Trends in Confirmed COVID-19 Cases in the Korean Military Before and After the Emergence of the Omicron Variant. <i>Journal of Korean Medical Science</i> , 2022, 37, .   | 2.5  | 2         |
| 198 | Age-specific Mortality Associated with COVID-19 and Seasonal Influenza in Japan: Using Multiple Population-based Databases. <i>Annals of Clinical Epidemiology</i> , 2022, 4, 129-132.                              | 1.2  | 2         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 199 | Voice Features of Sustained Phoneme as COVID-19 Biomarker. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2022, 10, 1-9.   | 3.7  | 8         |
| 200 | Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2211249.   | 1.7  | 14        |
| 201 | SARS-CoV-2 Nasopharyngeal Viral Load in Individuals Infected with BA.2, Compared to Alpha, Gamma, Delta and BA.1 Variants: A Single-Center Comparative Analysis. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4  | 0         |
| 202 | Evidence for Telemedicine's Ongoing Transformation of Health Care Delivery Since the Onset of COVID-19: Retrospective Observational Study. <i>JMIR Formative Research</i> , 2022, 6, e38661.  | 1.4  | 7         |
| 203 | How Do We Stop the Spread of SARS-CoV-2 in Young Children?. <i>JAMA Network Open</i> , 2022, 5, e2227357.   | 5.9  | 0         |
| 205 | Intensive care unit resources and patient-centred outcomes in severe COVID-19: a prospective single-centre economic evaluation. <i>Anaesthesia</i> , 2022, 77, 1336-1345.   | 3.8  | 5         |
| 206 | Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases. <i>Clinical Infectious Diseases</i> , 2023, 76, e18-e25.  | 5.8  | 15        |
| 207 | Misclassification bias in estimating clinical severity of SARS-CoV-2 variants. <i>Lancet, The</i> , 2022, 400, 809.   | 13.7 | 3         |
| 208 | Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. <i>Nature Communications</i> , 2022, 13, .  | 12.8 | 89        |
| 209 | Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. <i>Frontiers in Public Health</i> , 0, 10, .   | 2.7  | 7         |
| 211 | Potential Use of Exhaled Breath Condensate for Diagnosis of SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2022, 12, 2245.  | 2.6  | 5         |
| 212 | Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. <i>Scientific Reports</i> , 2022, 12, .   | 3.3  | 6         |
| 213 | Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 858-868. | 2.7  | 26        |
| 214 | New insights into human immune memory from SARS-CoV-2 infection and vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 0, , .   | 5.7  | 5         |
| 215 | COVID-19 in Older Adults at the Time of the Omicron Variant. <i>Journal of Clinical Medicine</i> , 2022, 11, 5273.  | 2.4  | 3         |
| 216 | COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022. <i>Journal of Medical Virology</i> , 2023, 95, .   | 5.0  | 10        |
| 218 | Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1757-1766.  | 0.9  | 10        |
| 220 | COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups. <i>Infectious Diseases and Therapy</i> , 2022, 11, 2045-2061.  | 4.0  | 16        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 222 | High mortality and morbidity among vaccinated residents infected with the SARS-CoV-2 Omicron variant during an outbreak in a nursing home in Kyoto City, Japan. <i>American Journal of Infection Control</i> , 2023, 51, 800-806.  | 2.3  | 7         |
| 223 | Misclassification bias in estimating clinical severity of SARS-CoV-2 variants – Authors' reply. <i>Lancet, The</i> , 2022, 400, 809-810.   | 13.7 | 2         |
| 224 | The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. <i>Journal of Medical Virology</i> , 2023, 95, .  | 5.0  | 71        |
| 225 | Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. <i>Cell Reports Medicine</i> , 2022, 3, 100743.   | 6.5  | 19        |
| 226 | Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127. <i>Frontiers in Public Health</i> , 0, 10, .   | 2.7  | 1         |
| 227 | A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .   | 3.0  | 4         |
| 229 | Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. <i>Blood</i> , 2022, 140, 2773-2787.  | 1.4  | 40        |
| 230 | Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. <i>Frontiers in Immunology</i> , 0, 13, .   | 4.8  | 20        |
| 231 | Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003992.  | 8.4  | 83        |
| 232 | Effectiveness of Inactivated SARS-CoV-2 Vaccines During a Delta Variant Outbreak in Hunan Province, China: A Retrospective Cohort Study. <i>Zoonoses</i> , 2022, 2, .  | 1.1  | 0         |
| 233 | Reappraisal of Coronavirus Disease 2019 Risk for Patients With Inflammatory Bowel Disease: Withdrawal of the British Society of Gastroenterology Inflammatory Bowel Disease Risk Grid. <i>Gastroenterology</i> , 2023, 164, 2-4.   | 1.3  | 0         |
| 234 | Neurological consequences of COVID-19. <i>Pharmacological Reports</i> , 2022, 74, 1208-1222.   | 3.3  | 10        |
| 235 | Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia. <i>Lung</i> , 2022, 200, 573-577.   | 3.3  | 11        |
| 236 | Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants. <i>Journal of Infectious Diseases</i> , 2023, 227, 332-338.  | 4.0  | 9         |
| 237 | Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment. <i>Applied Mathematical Modelling</i> , 2023, 114, 447-465.   | 4.2  | 23        |
| 238 | The disease burden of Delta and Omicron variants of severe acute respiratory syndrome coronavirus 2 in a predominantly vaccinated and healthy cohort. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1659-1661.  | 6.0  | 1         |
| 241 | Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. <i>Lancet, The</i> , 2022, 400, 1213-1222. | 13.7 | 163       |
| 242 | Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents. <i>Journal of Medical Virology</i> , 2023, 95, .   | 5.0  | 13        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 243 | Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies. <i>Transplant International</i> , 0, 35, .  | 1.6  | 4         |
| 244 | An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, .  | 6.0  | 8         |
| 245 | Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1129-1136.                              | 10.7 | 33        |
| 247 | An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1695-1700. | 1.8  | 1         |
| 248 | Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B.1.1.529 Omicron Epidemic: A Service Evaluation. <i>Open Forum Infectious Diseases</i> , 2022, 9, .                       | 0.9  | 5         |
| 249 | Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era. <i>Open Forum Infectious Diseases</i> , 2022, 9, .   | 0.9  | 15        |
| 250 | SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis. <i>Journal of Clinical Virology</i> , 2022, 157, 105299.                  | 3.1  | 5         |
| 251 | The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e38196.                               | 2.6  | 10        |
| 253 | Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation in France. <i>Nature Communications</i> , 2022, 13, .  | 12.8 | 33        |
| 254 | Is long COVID the next global health crisis?. <i>Journal of Global Health</i> , 0, 12, .   | 2.7  | 17        |
| 255 | Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. <i>Nature Communications</i> , 2022, 13, .  | 12.8 | 24        |
| 256 | Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1831-1841.                        | 4.4  | 10        |
| 257 | Exploring COVID-19 transmission patterns and key factors during epidemics caused by three major strains in Asia. <i>Journal of Theoretical Biology</i> , 2023, 557, 111336.  | 1.7  | 4         |
| 258 | SARS-CoV-2â€™The Role of Natural Immunity: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 6272.   | 2.4  | 12        |
| 259 | Evaluation of clinical harm associated with Omicron hospital-onset COVID-19 infection. <i>Journal of Infection</i> , 2023, 86, 66-117.   | 3.3  | 2         |
| 260 | A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains. <i>Journal of Clinical Practice</i> , 2022, 13, 43-55.  | 0.6  | 3         |
| 261 | Comparing the survival of adult inpatients with COVID-19 during the wild-type, Delta, and Omicron emergence. <i>Public Health</i> , 2022, 213, 124-126.  | 2.9  | 6         |
| 262 | Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France. <i>Frontiers in Medicine</i> , 0, 9, . | 2.6  | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 264 | The emergence of new SARS-CoV-2 omicron subvariants introduces uncertainty about the end of the COVID-19 pandemic. <i>Frontiers in Medicine</i> , 0, 9, .   | 2.6 | 2         |
| 265 | Mandatory COVID-19 vaccination for healthcare personnel in the era of new SARS-CoV-2 variants. <i>Vaccine</i> , 2022, 40, 7167-7169.  | 3.8 | 4         |
| 266 | The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection. <i>Vaccines</i> , 2022, 10, 1699.                         | 4.4 | 15        |
| 267 | Epidemiological characteristics of Omicron and Delta SARS-CoV-2 variant infection in Santiago, Chile. <i>Frontiers in Public Health</i> , 0, 10, .  | 2.7 | 5         |
| 268 | Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination. <i>Journal of Clinical Medicine</i> , 2022, 11, 6348.                              | 2.4 | 2         |
| 269 | Rapid investigation of BA.4/BA.5 cases in France. <i>Frontiers in Public Health</i> , 0, 10, .  | 2.7 | 6         |
| 270 | Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 167-176. | 9.1 | 71        |
| 271 | Circulating Dynamics of SARS-CoV-2 Variants between April 2021 and February 2022 in Turkey. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-7.                            | 1.9 | 5         |
| 272 | Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 883-891.  | 1.9 | 5         |
| 273 | SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 58.                            | 2.9 | 6         |
| 274 | Vaccination, symptomatic infection and negative conversion of viral RNA by body mass index, diabetes, and age: An observational study. <i>Vaccine</i> , 2022, 40, 6900-6907.                                      | 3.8 | 1         |
| 275 | Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals. <i>BMC Infectious Diseases</i> , 2022, 22, .                         | 2.9 | 19        |
| 276 | Differential activation of human neutrophils by SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 13, .   | 4.8 | 4         |
| 277 | Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. <i>Vaccines</i> , 2022, 10, 1762.  | 4.4 | 7         |
| 278 | Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .                      | 4.0 | 0         |
| 279 | Validation of RT-qPCR test for SARS-CoV-2 in saliva specimens. <i>Journal of Infection and Public Health</i> , 2022, 15, 1403-1408.   | 4.1 | 1         |
| 280 | The first 2 years of COVID-19 in Italy: Incidence, lethality, and health policies. <i>Frontiers in Public Health</i> , 0, 10, .   | 2.7 | 10        |
| 281 | The German COVID-19 Digital Contact Tracing App: A Socioeconomic Evaluation. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14318.  | 2.6 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 283 | Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. <i>BMC Infectious Diseases</i> , 2022, 22, .   | 2.9 | 5         |
| 284 | Epidemiology and Clinical Presentation of COVID-19 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 1-26.  | 5.1 | 10        |
| 286 | The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14057.  | 4.1 | 4         |
| 287 | Variable detection of Omicron-BA.1 and -BA.2 by SARS-CoV-2 rapid antigen tests. <i>Medical Microbiology and Immunology</i> , 2023, 212, 13-23.  | 4.8 | 8         |
| 288 | Emergence of SARS-CoV-2 Omicron Variant and strategies for tackling the infection. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .  | 2.7 | 9         |
| 289 | The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, . | 3.9 | 8         |
| 290 | Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand. <i>International Journal of Infectious Diseases</i> , 2023, 126, 31-38.                                     | 3.3 | 18        |
| 291 | Fatality rate, risk factors, and functional decline in peritoneal dialysis patients with coronavirus disease 2019: A nationwide cohort study. <i>Frontiers in Medicine</i> , 0, 9, .  | 2.6 | 1         |
| 292 | What is the place in therapy for nirmatrelvir/ritonavir?. <i>BMJ Evidence-Based Medicine</i> , 2023, 28, 287-290.   | 3.5 | 1         |
| 294 | Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 6600.  | 2.4 | 3         |
| 295 | The Impact of Demographic, Clinical Characteristics and the Various COVID-19 Variant Types on All-Cause Mortality: A Case-Series Retrospective Study. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 100.   | 2.5 | 2         |
| 296 | Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients. <i>BMC Infectious Diseases</i> , 2022, 22, .  | 2.9 | 2         |
| 297 | Clinical characteristics and short-term recovery of hyposmia in hospitalized non-severe COVID-19 patients with Omicron variant in Shanghai, China. <i>Frontiers in Medicine</i> , 0, 9, .   | 2.6 | 6         |
| 298 | Changing trends of patient characteristics and treatment pathways during the COVID-19 pandemic: A cross-sectional analysis of 72,459 inpatient cases from the German Helios database. <i>Frontiers in Public Health</i> , 0, 10, .  | 2.7 | 0         |
| 299 | Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. <i>BMJ, The</i> , 0, , e071932.  | 6.0 | 42        |
| 300 | Detection of the SARS-CoV-2 Omicron Variant in COVID-19 Patients from South Tangerang Using SNP-Probes S371L and K417N. <i>Journal of Pure and Applied Microbiology</i> , 0, , .  | 0.9 | 0         |
| 301 | Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study. <i>Vaccines</i> , 2022, 10, 1914.  | 4.4 | 2         |
| 302 | Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. <i>Expert Review of Vaccines</i> , 2023, 22, 1-16.  | 4.4 | 21        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 303 | The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections. <i>Intensive Care Research</i> , 0, , .   | 0.6 | 0         |
| 304 | Evolution and Control of COVID-19 Epidemic in Hong Kong. <i>Viruses</i> , 2022, 14, 2519.  | 3.3 | 20        |
| 305 | Adjusting intervention strategies for mental health of COVID-19 patients: A network analysis based on a survey in Omicron-infected patients. <i>Frontiers in Public Health</i> , 0, 10, .  | 2.7 | 3         |
| 306 | Study of the Deep Processes of COVID-19 in Russia: Finding Ways to Identify Preventive Measures. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14714.   | 2.6 | 1         |
| 307 | Biosafety protection and workflow of clinical microbiology laboratory under COVID-19: A review. <i>Medicine (United States)</i> , 2022, 101, e31740.   | 1.0 | 2         |
| 308 | COVID-19 Vaccination Hesitancy in Mexico City among Healthy Adults and Adults with Chronic Diseases: A Survey of Complacency, Confidence, and Convenience Challenges in the Transition to Endemic Control. <i>Vaccines</i> , 2022, 10, 1944.   | 4.4 | 1         |
| 309 | Hepatic dysfunctions in COVID-19 patients infected by the omicron variant of SARS-CoV-2. <i>Frontiers in Public Health</i> , 0, 10, .  | 2.7 | 2         |
| 310 | Comparison of the causes of death associated with delta and Omicron SARS-CoV-2 variants infection. <i>Journal of Infection and Public Health</i> , 2023, 16, 133-135.  | 4.1 | 4         |
| 311 | SARS-CoV-2 infection among patients with autoimmune rheumatic diseases; comparison between the Delta and Omicron waves in Israel. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152129.  | 3.4 | 6         |
| 312 | Neurological Manifestations of hospitalized patients with mild to moderate infection with SARS-CoV-2 Omicron variant in Shanghai, China. <i>Journal of Infection and Public Health</i> , 2023, 16, 155-162.  | 4.1 | 9         |
| 313 | Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom. <i>Lancet Regional Health - Europe</i> , The, 2023, 25, 100556.   | 5.6 | 55        |
| 314 | Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis. <i>Translational Oncology</i> , 2023, 28, 101605.   | 3.7 | 5         |
| 315 | Analysis of SARS-CoV-2 genomic surveillance data during the Delta and Omicron waves at a Saudi tertiary referral hospital. <i>Journal of Infection and Public Health</i> , 2023, 16, 171-181.  | 4.1 | 2         |
| 316 | Quantitative evaluation of the role of Fangcang shelter hospitals in the control of Omicron transmission: A case study of the outbreak in Shanghai, China in 2022. <i>One Health</i> , 2023, 16, 100475.   | 3.4 | 5         |
| 317 | Reinfección por SARS-CoV-2: infección por las variantes delta y Ómicron en un periodo de 20 días. <i>Revista De Medicina De Laboratorio</i> , 2022, , .  | 0.0 | 0         |
| 318 | SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis. <i>JMIR Bioinformatics and Biotechnology</i> , 0, 4, e42700.  | 0.9 | 2         |
| 319 | Statistics in Times of Increasing Uncertainty. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2022, 185, 1471-1496.   | 1.1 | 1         |
| 320 | Statistical Analysis of Mortality Rates of Coronavirus Disease 2019 (COVID-19) Patients in Japan Across the 4C Mortality Score Risk Groups, Age Groups, and Epidemiological Waves: A Report From the Nationwide COVID-19 Cohort. <i>Open Forum Infectious Diseases</i> , 2023, 10, . | 0.9 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 321 | An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .   | 4.8 | 7         |
| 322 | Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience. <i>Infectious Diseases and Therapy</i> , 2023, 12, 257-271.   | 4.0 | 26        |
| 323 | Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7ÅM people. <i>BMC Infectious Diseases</i> , 2022, 22, .  | 2.9 | 5         |
| 324 | The Preventive Role of mRNA Vaccines in Reducing Death among Moderate Omicron-Infected Patients: A Follow-Up Study. <i>Viruses</i> , 2022, 14, 2622.  | 3.3 | 2         |
| 325 | Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and Åomicron predominance in Thailand: a test-negative, case-control study. , 2023, 10, 100121.  |     | 12        |
| 326 | Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2-Å€Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .   | 1.4 | 3         |
| 327 | Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection-Å€Final Update of a Living, Rapid Review. <i>Annals of Internal Medicine</i> , 2023, 176, 85-91.  | 3.9 | 6         |
| 328 | Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians. <i>Annals of Internal Medicine</i> , 2023, 176, 92-104.  | 3.9 | 9         |
| 329 | Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .   | 1.4 | 1         |
| 331 | Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis. <i>Journal of Translational Medicine</i> , 2022, 20, .  | 4.4 | 5         |
| 333 | Investigation of SARS-CoV-2 Variants and Their Effect on SARS-CoV-2 Monoclonal Antibodies, Convalescent and Vaccine Plasma by a Novel Web Tool. <i>Diagnostics</i> , 2022, 12, 2869.  | 2.6 | 1         |
| 334 | Impact of community asymptomatic rapid antigen testing on covid-19 related hospital admissions: synthetic control study. <i>BMJ</i> , The, 0, , e071374.  | 6.0 | 14        |
| 335 | Antiviral Treatment of COVID-19 Pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .   | 2.1 | 0         |
| 336 | Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-Å€March, 2022: a national, observational, test-negative, case-control study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 435-444. | 9.1 | 47        |
| 337 | Comparing the demographics and laboratory biomarkers of the COVID-19 Omicron wave and the Alpha wave in a predominantly Afro-Caribbean patient population in New York City. <i>Pneumonia (Nathan Qld)</i> , 2022, 14, .   | 6.1 | 1         |
| 338 | How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .   | 3.8 | 2         |
| 339 | Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .  | 0.9 | 3         |
| 340 | Factors Associated With Vaccine-Induced T-Cell Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Kidney Transplant Recipients. <i>Journal of Infectious Diseases</i> , 0, , .   | 4.0 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 341 | Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. <i>ELife</i> , 0, 11, .   | 6.0 | 9         |
| 342 | Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance. <i>Expert Review of Vaccines</i> , 2023, 22, 90-103.  | 4.4 | 7         |
| 343 | Clinical characteristics of patients infected with novel coronavirus wild strain, Delta variant strain and Omicron variant strain in Quanzhou: A real-world study. <i>Experimental and Therapeutic Medicine</i> , 2022, 25, .     | 1.8 | 9         |
| 344 | Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants. <i>Virology Journal</i> , 2022, 19, .   | 3.4 | 3         |
| 345 | Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients. <i>Vaccines</i> , 2022, 10, 2117.   | 4.4 | 0         |
| 347 | Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 555-558.   | 3.0 | 11        |
| 348 | COVID-19 and elite sport: Cardiovascular implications and return-to-play. <i>Progress in Cardiovascular Diseases</i> , 2023, 76, 61-68.   | 3.1 | 2         |
| 349 | Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern. <i>Npj Vaccines</i> , 2022, 7, .  | 6.0 | 9         |
| 350 | The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. <i>International Journal of Infectious Diseases</i> , 2022, , .  | 3.3 | 5         |
| 351 | Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. <i>Clinical Infectious Diseases</i> , 2023, 76, 1468-1475.   | 5.8 | 15        |
| 352 | Clinical Characteristics and Outcomes of Patients Hospitalized With COVID-19 During the First 4 Waves in Zambia. <i>JAMA Network Open</i> , 2022, 5, e2246152.  | 5.9 | 0         |
| 355 | Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. <i>Clinical Infectious Diseases</i> , 2023, 76, 1403-1411. | 5.8 | 52        |
| 357 | Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases. <i>Bone Marrow Transplantation</i> , 2023, 58, 340-342.   | 2.4 | 7         |
| 359 | The impact of COVID-19 vaccination campaign in Hong Kong SAR China and Singapore. <i>Infectious Disease Modelling</i> , 2023, 8, 101-106.   | 1.9 | 5         |
| 361 | COVID-19 pneumonia: lessons learned, challenges, and preparing for the future. , 2022, 28, 576-585.   |     | 2         |
| 362 | Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. <i>Microorganisms</i> , 2023, 11, 30.   | 3.6 | 11        |
| 363 | Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts. <i>Viruses</i> , 2022, 14, 2736.   | 3.3 | 10        |
| 364 | Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022. <i>JAMA Network Open</i> , 2022, 5, e2245861.                                   | 5.9 | 9         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 366 | Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , .                                   | 0.5 | 3         |
| 367 | Trends in managing COVID-19 from an emerging infectious disease to a common respiratory infectious disease: What are the subsequent impacts on and new challenges for healthcare systems?. <i>BioScience Trends</i> , 2022, 16, 381-385. | 3.4 | 8         |
| 368 | Viral dynamics during SARS-CoV-2 omicron infection highlight presymptomatic and asymptomatic infectiousness. <i>Journal of Infection</i> , 2022, , .   | 3.3 | 3         |
| 369 | Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece. <i>Journal of Clinical Medicine</i> , 2022, 11, 7172.  | 2.4 | 7         |
| 370 | Use of remdesivir for COVID-19 in patients with hematologic cancer. <i>Clinical and Experimental Medicine</i> , 0, , .   | 3.6 | 2         |
| 371 | Omicron variants of SARS-CoV-2 and long COVID. <i>Frontiers in Immunology</i> , 0, 13, .   | 4.8 | 5         |
| 372 | Comparative Study of Audiovestibular Symptoms between Early and Late Variants of COVID-19. <i>Audiology Research</i> , 2022, 12, 680-695.  | 1.8 | 5         |
| 373 | Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. <i>Epidemics</i> , 2022, 41, 100657.  | 3.0 | 10        |
| 374 | Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient Clinical Outcome. <i>Clinical Infectious Diseases</i> , 2023, 76, 1539-1549.   | 5.8 | 16        |
| 375 | Complications Following Elective Major Noncardiac Surgery Among Patients With Prior SARS-CoV-2 Infection. <i>JAMA Network Open</i> , 2022, 5, e2247341.  | 5.9 | 11        |
| 376 | The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.  | 3.0 | 12        |
| 377 | Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.   | 5.7 | 33        |
| 378 | Molnupiravir for SARS-CoV-2 infection: Public health and policy implications. <i>Journal of Infection</i> , 2022, , .  | 3.3 | 4         |
| 379 | Nirmatrelvir-ritonavir might only be effective in elderly patients. <i>Journal of Medical Virology</i> , 2023, 95, .   | 5.0 | 0         |
| 380 | Social participation and mental health of immunocompromised individuals before and after COVID-19 vaccination-Results of a longitudinal observational study over three time points. <i>Frontiers in Psychiatry</i> , 0, 13, .            | 2.6 | 6         |
| 382 | Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France. <i>Antibiotics</i> , 2023, 12, 88.                     | 3.7 | 1         |
| 383 | Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database. <i>Viruses</i> , 2023, 15, 149.   | 3.3 | 22        |
| 384 | Current and Emerging Knowledge in COVID-19. <i>Radiology</i> , 2023, 306, .  | 7.3 | 30        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 385 | COVID-19 patientsâ€™ clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. <i>Indian Journal of Medical Microbiology</i> , 2023, 41, 28-32.  | 0.8  | 2         |
| 386 | Transmission dynamics and associated mortality of nosocomial COVID-19 throughout 2021: a retrospective study at a large teaching hospital in London. <i>Journal of Hospital Infection</i> , 2023, 133, 62-69.  | 2.9  | 4         |
| 387 | Gut Microbiota in Coronavirus Disease 2019. , 2023, , 289-302.   |      | 0         |
| 390 | Decreased Clinical Severity of Pediatric Acute COVID-19 and MIS-C and Increase of Incidental Cases during the Omicron Wave in Comparison to the Delta Wave. <i>Viruses</i> , 2023, 15, 180.  | 3.3  | 12        |
| 391 | Value of hospital datasets of COVID-19 patients across different pandemic periods: challenges and opportunities. <i>Internal and Emergency Medicine</i> , 0, , .   | 2.0  | 0         |
| 392 | Mitigation of Socio-Economical Inequalities on the Profile of Healthcare Workers Infected with SARS-CoV-2 upon Vaccination: The Experience of a Brazilian Public Healthcare Institution during the Omicron Wave. <i>Covid</i> , 2023, 3, 65-81.  | 1.5  | 0         |
| 394 | COVID-19 coronavirus infection in children: Clinical presentation, diagnosis, vaccination, and treatment. <i>Rossiyskiy Vestnik Perinatologii i Pediatrii</i> , 2023, 67, 14-24.   | 0.3  | 0         |
| 398 | The pattern of cytokines expression and dynamic changes of renal function at 6 months in patients with Omicron COVID-19. <i>Journal of Medical Virology</i> , 2023, 95, .  | 5.0  | 2         |
| 399 | Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 163-175. | 10.7 | 18        |
| 400 | Analysis of SARS-CoV-2 Cases, COVID-19 Outcomes and Vaccinations, during the Different SARS-CoV-2 Variants in Greece. <i>Vaccines</i> , 2023, 11, 126.   | 4.4  | 2         |
| 402 | An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. <i>IScience</i> , 2023, 26, 105949.   | 4.1  | 1         |
| 403 | Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. <i>Lancet, The</i> , 2023, 401, 447-457.   | 13.7 | 62        |
| 404 | Psychological Impact of COVID-19 Lockdown and Its Evolution: A Case Study Based on Internet Searching Data during the Lockdown of Wuhan 2020 and Shanghai 2022. <i>Healthcare (Switzerland)</i> , 2023, 11, 289.   | 2.0  | 4         |
| 405 | SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .   | 28.6 | 160       |
| 406 | The Relationship of COVID-19 Vaccination with Mortality Among 86,732 Hospitalized Patients: Subpopulations, Patient Factors, and Changes over Time. <i>Journal of General Internal Medicine</i> , 2023, 38, 1248-1255.   | 2.6  | 10        |
| 407 | Is the 4C Score Still a Valid Item to Predict In-Hospital Mortality in People with SARS-CoV-2 Infections in the Omicron Variant Era?. <i>Life</i> , 2023, 13, 183.   | 2.4  | 4         |
| 409 | Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. <i>JAMA Network Open</i> , 2022, 5, e2248664.   | 5.9  | 17        |
| 411 | A descriptive analysis for the comparison of the symptoms and severity of coronavirus disease 2019 (COVID-19) in each epidemic period in Okayama City. <i>Okayama Igakkai Zasshi</i> , 2022, 134, 160-165.   | 0.0  | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 412 | Management and operation of extra-large Fangcang hospitals: experience and lessons from containing the highly contagious SARS-CoV-2 Omicron in Shanghai, China. <i>Frontiers of Medicine</i> , 0, , .  | 3.4 | 0         |
| 413 | The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants. <i>Scientific Reports</i> , 2022, 12, .   | 3.3 | 1         |
| 414 | Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1). <i>Clinical Microbiology and Infection</i> , 2023, 29, 642-650.            | 6.0 | 5         |
| 415 | Clinical severity according to the primary infection variant in patients with suspected SARS-CoV-2 reinfection in Korea. <i>Epidemiology and Health</i> , 0, 45, e2023007.   | 1.9 | 3         |
| 416 | Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November) Tj ETQq0 0.0 rgBT /Overlock 10   | 3.3 | 14        |
| 417 | Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. <i>PLoS Medicine</i> , 2023, 20, e1004086.  | 8.4 | 24        |
| 418 | Retrospective Analysis of the Duration of Hospitalization of Imported Patients Infected with SARS-CoV-2 in Guangzhou, 2021. <i>Infectious Diseases &amp; Immunity</i> , 2023, 3, 36-39.  | 0.6 | 0         |
| 419 | Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies. <i>Frontiers in Immunology</i> , 0, 13, .  | 4.8 | 2         |
| 420 | Nirmatrelvirâ€“ritonavir therapy and COVIDâ€“19 vaccination improve clinical outcomes of SARSâ€“CoVâ€“2 Omicron variant infection. <i>Journal of Medical Virology</i> , 2023, 95, .  | 5.0 | 5         |
| 421 | Severity of COVID-19 among Residents in Aged Care Facilities in Victoria, Australia: A Retrospective Cohort Study Comparing the Delta and Omicron Epidemic Periods. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 434-440.e5.     | 2.5 | 0         |
| 422 | Significantly lower infection fatality rates associated with SARS-CoV-2 Omicron (B.1.1.529) infection in children and young people: Active, prospective national surveillance, January-March 2022, England. <i>Journal of Infection</i> , 2023, 86, 397-398. | 3.3 | 9         |
| 423 | Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave. <i>Viruses</i> , 2023, 15, 297.  | 3.3 | 6         |
| 425 | Is there a role for RDTs as we live with COVID-19? An assessment of different strategies. <i>BMJ Global Health</i> , 2023, 8, e010690.   | 4.7 | 1         |
| 427 | Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19â€“related deaths among people with multimorbidity: a cohort study. <i>Cmaj</i> , 2023, 195, E143-E152.  | 2.0 | 9         |
| 428 | Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 556-567.                           | 9.1 | 242       |
| 429 | Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US. <i>JAMA Network Open</i> , 2023, 6, e2253590.  | 5.9 | 51        |
| 430 | Remdesivir for the treatment of COVID-19. <i>The Cochrane Library</i> , 2023, 2023, .  | 2.8 | 17        |
| 431 | Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. <i>Eurosurveillance</i> , 2023, 28, .                                | 7.0 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 432 | Understanding COVID-19 Vaccine Effectiveness against Death Using a Novel Measure: COVID Excess Mortality Percentage. <i>Vaccines</i> , 2023, 11, 379.  | 4.4 | 4         |
| 433 | SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. <i>Diagnostics</i> , 2023, 13, 559.   | 2.6 | 12        |
| 434 | Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis. <i>Pediatric Infectious Disease Journal</i> , 2023, 42, 232-239.   | 2.0 | 17        |
| 435 | Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. <i>Epidemiology and Infection</i> , 2023, 151, .                                    | 2.1 | 19        |
| 436 | Real-world use of nirmatrelvir+ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 696-705. | 9.1 | 50        |
| 438 | Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves. <i>JAMA Network Open</i> , 2023, 6, e231181.   | 5.9 | 7         |
| 440 | SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?. <i>Journal of Translational Medicine</i> , 2023, 21, .   | 4.4 | 9         |
| 441 | Influence of vaccination on adverse health outcomes after SARS-CoV-2 infection among individuals with alcohol use disorder: a population-based study. <i>Addiction</i> , 0, .  | 3.3 | 0         |
| 442 | Association of preoperative COVID-19 and postoperative respiratory morbidity during the Omicron epidemic wave: the DROMIS-22 multicentre prospective observational cohort study. <i>EClinicalMedicine</i> , 2023, 58, 101881.                | 7.1 | 7         |
| 443 | Blood Biomarkers from the Emergency Department Disclose Severe Omicron COVID-19-Associated Outcomes. <i>Microorganisms</i> , 2023, 11, 925.  | 3.6 | 1         |
| 444 | Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.                      | 7.3 | 46        |
| 445 | The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs. <i>Environmental Research</i> , 2023, 225, 115612.  | 7.5 | 7         |
| 446 | Clinical prediction rules for adverse evolution in patients with COVID-19 by the Omicron variant. <i>International Journal of Medical Informatics</i> , 2023, 173, 105039.   | 3.3 | 0         |
| 447 | Epidemiologic and economic modelling of optimal COVID-19 policy: public health and social measures, masks and vaccines in Victoria, Australia. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 32, 100675.                       | 2.9 | 5         |
| 448 | Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China. <i>Journal of Infection and Public Health</i> , 2023, 16, 422-429.  | 4.1 | 11        |
| 449 | Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. <i>Blood Advances</i> , 2023, 7, 5691-5697.  | 5.2 | 4         |
| 450 | Comparison of Delta and Omicron variant of COVID-19 infection cases in Montenegro. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2023, 151, 10-14.  | 0.2 | 0         |
| 451 | Convalescent plasma for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2023, 2023, .  | 2.8 | 10        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 452 | Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )</i> , 2024, 42, 187-194.   | 0.3  | 3         |
| 453 | Severity of SARS-CoV-2 Omicron variant infection in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2023, 42, 558-561.  | 0.6  | 4         |
| 455 | Minimising school disruption under high incidence conditions due to the Omicron variant in France, Switzerland, Italy, in January 2022. <i>Eurosurveillance</i> , 2023, 28, .   | 7.0  | 3         |
| 456 | Identification of natural compounds as SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation. <i>Frontiers in Microbiology</i> , 0, 13, .  | 3.5  | 2         |
| 457 | Chest computed tomography findings of the Omicron variants of SARS-CoV-2 with different cycle threshold values. <i>World Journal of Clinical Cases</i> , 0, 11, 756-763.  | 0.8  | 0         |
| 458 | Corticosteroids and Outcomes in Solid Organ Transplant Recipients Infected With Severe Acute Respiratory Syndrome Coronavirus 2. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2023, 7, 99-108.  | 2.4  | 0         |
| 459 | Change over Time in the Risk of Death among Japanese COVID-19 Cases Caused by the Omicron Variant Depending on Prevalence of Sublineages. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2779.  | 2.6  | 2         |
| 460 | Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort). <i>Viruses</i> , 2023, 15, 438.   | 3.3  | 9         |
| 462 | The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .  | 2.4  | 17        |
| 463 | Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic. <i>Current Opinion in Rheumatology</i> , 2023, 35, 175-184.  | 4.3  | 9         |
| 464 | The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: a systematic review and meta-analysis. <i>Irish Journal of Medical Science</i> , 2023, 192, 2897-2904.                                      | 1.5  | 2         |
| 465 | Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP. <i>Journal of Clinical Medicine</i> , 2023, 12, 1388.  | 2.4  | 1         |
| 467 | Characteristics and outcomes of COVID-19 home monitoring in Saudi Arabia during the second and third waves. <i>IJID Regions</i> , 2023, 6, 142-145.   | 1.3  | 2         |
| 468 | SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort. <i>Virology Journal</i> , 2023, 20, .   | 3.4  | 2         |
| 469 | Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 439-452. | 10.7 | 69        |
| 471 | Impact of COVID-19 on Cardiovascular Disease. <i>Viruses</i> , 2023, 15, 508.   | 3.3  | 15        |
| 473 | Comparing SARS-CoV-2 variants among children and adolescents in Germany: relative risk of COVID-19-related hospitalization, ICU admission and mortality. <i>Infection</i> , 2023, 51, 1357-1367.  | 4.7  | 7         |
| 474 | Risk of Admission to the Pediatric Intensive Care Unit for SARS-CoV-2 Delta and Omicron Infections. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2023, 12, 189-197.  | 1.3  | 3         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 475 | Population-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic. <i>Open Forum Infectious Diseases</i> , 2023, 10, .  | 0.9  | 0         |
| 476 | Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis. <i>Antibiotics</i> , 2023, 12, 393.  | 3.7  | 10        |
| 478 | Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland. <i>JAMA Network Open</i> , 2023, 6, e2255599.   | 5.9  | 19        |
| 479 | Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. <i>Med</i> , 2023, 4, 191-215.e9.  | 4.4  | 16        |
| 480 | Factors Influencing Antibody Response to SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2023, 11, 451.  | 4.4  | 4         |
| 481 | Costâ€“Benefit of Real-Time Multiplex PCR Testing of SARS-CoV-2 in German Hospitals. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3447.  | 2.6  | 2         |
| 482 | Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. <i>Lancet, The</i> , 2023, 401, 833-842.   | 13.7 | 151       |
| 484 | Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19â€“Associated Encounters in Adults During Delta and Omicron Predominance. <i>Journal of Infectious Diseases</i> , 2023, 227, 1348-1363.   | 4.0  | 4         |
| 485 | Simulating potential outbreaks of Delta and Omicron variants based on contact-tracing data: A modelling study in Fujian Province, China. <i>Infectious Disease Modelling</i> , 2023, 8, 270-281.   | 1.9  | 1         |
| 486 | SARS-CoV-2 Prevalence on and Incidence after Arrival in Travelers on Direct Flights from Cape Town, South Africa to Munich, Germany Shortly after Occurrence of the Omicron Variant in November/December 2021: Results from the OMTRAIR Study. <i>Pathogens</i> , 2023, 12, 354.           | 2.8  | 0         |
| 488 | Outcome of early treatment of <scp>SARSâ€“CoV</scp>â€“2 infection in patients with haematological disorders. <i>British Journal of Haematology</i> , 2023, 201, 628-639.   | 2.5  | 16        |
| 489 | Childrenâ€™s Symptoms with a Febrile Illness and a Positive or Negative Test of SARS-CoV-2 during the Omicron Wave. <i>Children</i> , 2023, 10, 419.   | 1.5  | 1         |
| 490 | Pathogen Distribution, Drug Resistance Risk Factors, and Construction of Risk Prediction Model for Drug-Resistant Bacterial Infection in Hospitalized Patients at the Respiratory Department During the COVID-19 Pandemic. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1107-1121. | 2.7  | 3         |
| 491 | Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. <i>Frontiers in Immunology</i> , 0, 14, .  | 4.8  | 3         |
| 493 | A case of COVID-19-associated fulminant myocarditis due to SARS-CoV-2 Omicron BA.2 sub-lineage in an unvaccinated female. <i>Journal of Cardiology Cases</i> , 2023, , .   | 0.5  | 0         |
| 495 | A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). <i>Medicine (United Tj ETQq</i> 1,1 0.784314 rgBT (C   | 1.0  | 17        |
| 496 | Surfing the Waves: Differences in Hospitalised COVID-19 Patients across 4 Variant Waves in a Belgian University Hospital. <i>Viruses</i> , 2023, 15, 618.  | 3.3  | 7         |
| 498 | Lung tropism in hospitalized patients following infection with SARS-CoV-2 variants from D614G to Omicron BA.2. <i>Communications Medicine</i> , 2023, 3, .   | 4.2  | 5         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 499 | Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan. <i>Access Microbiology</i> , 2023, 5, .  | 0.5  | 0         |
| 500 | Neuropathological features of SARS-CoV-2 delta and omicron variants. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 283-295.   | 1.7  | 7         |
| 501 | SARS-CoV-2 SUD2 and Nsp5 Conspire to Boost Apoptosis of Respiratory Epithelial Cells via an Augmented Interaction with the G-Quadruplex of Bclll. <i>MBio</i> , 0, , .  | 4.1  | 0         |
| 502 | The effects of obesity and metabolic abnormalities on severe COVID-19-related outcomes after vaccination: A population-based study. <i>Cell Metabolism</i> , 2023, 35, 585-600.e5.  | 16.2 | 6         |
| 503 | Mortality and burden of <sc>postâ€COVID</sc>â€19 syndrome have reduced with time across <sc>SARSâ€CoV</sc>â€2 variants in haematology patients. <i>British Journal of Haematology</i> , 2023, 201, 640-644.                                     | 2.5  | 10        |
| 504 | Â«Long COVIDÂ»: the current state of the problem. A review of foreign scientific and medical publications. <i>Physical and Rehabilitation Medicine Medical Rehabilitation</i> , 2023, 5, 52-79.   | 0.5  | 0         |
| 505 | COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100461.       | 2.6  | 8         |
| 506 | Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents. <i>Frontiers in Immunology</i> , 0, 14, .  | 4.8  | 6         |
| 507 | Favorable outcome of <sc>COVID</sc>â€19 in pediatric patients with primary immunodeficiency. <i>Pediatric Allergy and Immunology</i> , 2023, 34, .  | 2.6  | 1         |
| 508 | Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. <i>Journal of Infectious Diseases</i> , 2023, 228, 235-244.  | 4.0  | 1         |
| 509 | Impact of Vaccination and the Omicron Variant on COVID-19â€related Chest CT Findings: A Multicenter Study. <i>Radiology</i> , 2023, 307, .  | 7.3  | 11        |
| 510 | Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study. <i>Journal of Korean Medical Science</i> , 2023, 38, .                                | 2.5  | 10        |
| 512 | SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. <i>Frontiers in Immunology</i> , 0, 14, .  | 4.8  | 1         |
| 513 | Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study â€” Hohhot City, Inner Mongolia Autonomous Region, China, 2022. <i>China CDC Weekly</i> , 2023, 5, 218-222. | 2.3  | 3         |
| 514 | Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. <i>Clinical Infectious Diseases</i> , 2023, 77, 194-202.                      | 5.8  | 20        |
| 515 | Transmission of SARS-CoV-2 Omicron Variant under a Dynamic Clearance Strategy in Shandong, China. <i>Microbiology Spectrum</i> , 2023, 11, .  | 3.0  | 2         |
| 516 | Drug treatment of COVID-19 infection. <i>Current Opinion in Pulmonary Medicine</i> , 2023, 29, 174-183.   | 2.6  | 10        |
| 517 | Comparative Analysis of Clinical and CT Findings in Patients with SARS-CoV-2 Original Strain, Delta and Omicron Variants. <i>Biomedicines</i> , 2023, 11, 901.  | 3.2  | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 518 | Clinical Outcome and Prognosis of a Nosocomial Outbreak of COVID-19. <i>Journal of Clinical Medicine</i> , 2023, 12, 2279.   | 2.4 | 1         |
| 519 | Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis. <i>American Journal of Epidemiology</i> , 2023, 192, 1137-1147.   | 3.4 | 3         |
| 520 | Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity. <i>Vaccines</i> , 2023, 11, 668.   | 4.4 | 3         |
| 521 | A Novel SARS-CoV-2 Variant Omicron Disseminating Evaluation. <i>Lecture Notes in Networks and Systems</i> , 2023, , 47-57.   | 0.7 | 0         |
| 522 | Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6,037,144 coronavirus disease 2019-positive patients. <i>Clinical Microbiology and Infection</i> , 2023, 29, 835-844. | 6.0 | 29        |
| 524 | Challenges and Recent Advancements in COVID-19 Vaccines. <i>Microorganisms</i> , 2023, 11, 787.  | 3.6 | 1         |
| 525 | Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1611-1618.   | 2.7 | 2         |
| 527 | Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting. <i>Viruses</i> , 2023, 15, 811.   | 3.3 | 9         |
| 528 | Molecular Characterization and Cluster Analysis of SARS-CoV-2 Viral Isolates in Kahramanmaraş City, Turkey: The Delta VOC Wave within One Month. <i>Viruses</i> , 2023, 15, 802.   | 3.3 | 1         |
| 531 | Retrospective Analysis of Vaccination Status and Predominant Viral Variants in Patients Hospitalized with COVID-19 in Reus, Spain. <i>Viruses</i> , 2023, 15, 886.   | 3.3 | 0         |
| 532 | The disease severity of COVID-19 caused by Omicron variants: A brief review. <i>Annals of Clinical Epidemiology</i> , 2023, 5, 31-36.  | 1.2 | 2         |
| 533 | Do pathogens always evolve to be less virulent? The virulence-transmission trade-off in light of the COVID-19 pandemic. <i>Biologia Futura</i> , 0, , .  | 1.4 | 2         |
| 534 | Policy Disparities Between Singapore and Israel in Response to the First Omicron Wave. <i>Risk Management and Healthcare Policy</i> , 0, Volume 16, 489-502.   | 2.5 | 1         |
| 537 | Estimating infection fatality risk and ascertainment bias of COVID-19 in Osaka, Japan from February 2020 to January 2022. <i>Scientific Reports</i> , 2023, 13, .  | 3.3 | 1         |
| 538 | Characteristics of COVID-19 patients with multiorgan injury across the pandemic in a large academic health system in the Bronx, New York. <i>Heliyon</i> , 2023, 9, e15277.  | 3.2 | 4         |
| 539 | Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19. <i>JAMA Network Open</i> , 2023, 6, e237243.  | 5.9 | 8         |
| 540 | Standardized Cumulative Metrics of Excess Mortality to Monitor Health System Resilience Throughout COVID-19 and Other Respiratory Virus Resurgences. <i>American Journal of Epidemiology</i> , 2024, 193, 410-414.   | 3.4 | 0         |
| 541 | Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases. <i>Rheumatology International</i> , 2023, 43, 1033-1039.   | 3.0 | 3         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 542 | Situation and Spatial Analysis of the COVID-19 Epidemic in Business Establishments: Comparison between the Delta and Omicron Variants in Thailand, July 2021–May 2022. , 2022, 15, 114-122.  |      | 0         |
| 543 | Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study. <i>Nature Communications</i> , 2023, 14, .  | 12.8 | 8         |
| 544 | Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine. <i>Frontiers in Immunology</i> , 0, 14, .   | 4.8  | 4         |
| 545 | Comparative epidemic expansion of SARS-CoV-2 variants Delta and Omicron in the Brazilian State of Amazonas. <i>Nature Communications</i> , 2023, 14, .   | 12.8 | 5         |
| 546 | The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy. <i>PeerJ</i> , 0, 11, e15024.   | 2.0  | 4         |
| 547 | An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. <i>Nature Communications</i> , 2023, 14, .   | 12.8 | 11        |
| 549 | Drivers of SARS-CoV-2 testing behaviour: a modelling study using nationwide testing data in England. <i>Nature Communications</i> , 2023, 14, .  | 12.8 | 3         |
| 550 | Elder and booster vaccination associates with decreased risk of serious clinical outcomes in comparison of Omicron and Delta variant: A meta-analysis of SARS-CoV-2 infection. <i>Frontiers in Microbiology</i> , 0, 14, .                         | 3.5  | 1         |
| 552 | Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study. <i>BMC Infectious Diseases</i> , 2023, 23, .  | 2.9  | 1         |
| 553 | Persistence of the Omicron variant of SARS-CoV-2 in Australia: The impact of fluctuating social distancing. <i>PLOS Global Public Health</i> , 2023, 3, e0001427.  | 1.6  | 2         |
| 554 | Effectiveness, Immunogenicity and Harms of Additional SARS-CoV-2 Vaccine Doses in Kidney Transplant Recipients: A Systematic Review. <i>Vaccines</i> , 2023, 11, 863.  | 4.4  | 1         |
| 555 | The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries. <i>Frontiers in Public Health</i> , 0, 11, .   | 2.7  | 0         |
| 556 | Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies. <i>Open Forum Infectious Diseases</i> , 2023, 10, . | 0.9  | 2         |
| 557 | Epidemiological Surveillance Reveals the Rise and Establishment of the Omicron SARS-CoV-2 Variant in Brazil. <i>Viruses</i> , 2023, 15, 1017.  | 3.3  | 2         |
| 558 | Exhaled aerosols among PCR-confirmed SARS-CoV-2-infected children. <i>Frontiers in Pediatrics</i> , 0, 11, .   | 1.9  | 0         |
| 559 | Characteristics and clinical effectiveness of COVID-19 vaccination in hospitalized patients in Omicron-dominated epidemic wave – a nationwide study in Japan. <i>International Journal of Infectious Diseases</i> , 2023, 132, 84-88.              | 3.3  | 5         |
| 560 | Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. <i>Microbiology Spectrum</i> , 0, , .  | 3.0  | 0         |
| 561 | Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants: A population-based, matched cohort study. <i>PLoS ONE</i> , 2023, 18, e0282806.                 | 2.5  | 10        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 562 | Outcomes of influenza and COVID-19 inpatients in different phases of the SARS-CoV-2 pandemic: a single-centre retrospective caseâ€“control study. <i>Journal of Hospital Infection</i> , 2023, 138, 1-7.  | 2.9  | 2         |
| 563 | Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019â€“Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada. <i>Clinical Infectious Diseases</i> , 2023, 77, 805-815.               | 5.8  | 5         |
| 564 | Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK. <i>Nature Communications</i> , 2023, 14, .  | 12.8 | 10        |
| 565 | Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes. <i>JAMA Network Open</i> , 2023, 6, e239694.  | 5.9  | 6         |
| 566 | Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. <i>Lancet Public Health</i> , The, 2023, 8, e364-e377.                              | 10.0 | 21        |
| 567 | Predicting the negative conversion time of nonsevere COVIDâ€“19 patients using machine learning methods. <i>Journal of Medical Virology</i> , 2023, 95, .   | 5.0  | 1         |
| 568 | Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort. <i>ESMO Open</i> , 2023, 8, 101559.   | 4.5  | 0         |
| 569 | SARS-CoV-2 Omicron Specific Mutations Affecting Infectivity, Fusogenicity, and Partial TMPRSS2-Independency. <i>Viruses</i> , 2023, 15, 1129.   | 3.3  | 3         |
| 570 | Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients. <i>Nature Communications</i> , 2023, 14, .   | 12.8 | 3         |
| 571 | Inequities in COVID-19 Omicron infections and hospitalisations for MÃƒori and Pacific people in Te Manawa Taki Midland region, New Zealand. <i>Epidemiology and Infection</i> , 2023, 151, .  | 2.1  | 3         |
| 572 | <scp>COVID</scp>â€“19 infection in patients with haematological malignancies: A singleâ€“centre survey in the latest Omicron wave in China. <i>British Journal of Haematology</i> , 2023, 202, 31-39.   | 2.5  | 7         |
| 573 | Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers. <i>Vaccine</i> , 2023, 41, 3403-3409.   | 3.8  | 4         |
| 574 | Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England. <i>Journal of Infection</i> , 2023, 87, e8-e11.   | 3.3  | 5         |
| 575 | Mutations of SARS-CoV-2 and their impact on disease diagnosis and severity. <i>Informatics in Medicine Unlocked</i> , 2023, 39, 101256.   | 3.4  | 5         |
| 576 | What has vaccination against COVID-19 in CKD patients taught us?. <i>Journal of Nephrology</i> , 2023, 36, 1257-1266.   | 2.0  | 1         |
| 577 | Clinical surrogates of dysautonomia predict lethal outcome in COVID-19 on intensive care unit. <i>Neurological Research and Practice</i> , 2023, 5, .   | 2.0  | 0         |
| 578 | Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant. <i>Viruses</i> , 2023, 15, 1132.                                    | 3.3  | 4         |
| 579 | History of cerebrovascular disease but not dementia increases the risk for secondary vascular events during <scp>SARSâ€“CoV</scp>â€“2 infection with presumed Omicron variant: a retrospective observational study. <i>European Journal of Neurology</i> , 0, , . | 3.3  | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 580 | Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand. PLoS ONE, 2023, 18, e0284130.   | 2.5 | 3         |
| 581 | Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2023, 78, 1586-1598.  | 3.0 | 9         |
| 582 | Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine, 2023, 60, 102000.  | 7.1 | 27        |
| 583 | Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022. International Journal of Infectious Diseases, 2023, 133, 89-96.       | 3.3 | 1         |
| 584 | Continuous positive airway pressure in COVID-19-associated respiratory failure: improving patient care with a proforma. British Journal of Nursing, 2023, 32, 412-419.   | 0.7 | 0         |
| 585 | New-Onset Atrial Fibrillation in the Setting of COVID-19 Infection Is a Predictor of Mortality in Hospitalized Patients: CovAF-Study. Journal of Clinical Medicine, 2023, 12, 3500.  | 2.4 | 3         |
| 586 | Mortality in Catalonia during the summer of 2022 and its relation with high temperatures and COVID-19 cases. Frontiers in Public Health, 0, 11, .  | 2.7 | 0         |
| 587 | A Comparison of Clinical Presentations in Coronavirus Disease 2019 Caused by Different Omicron Variants in Japan: A Retrospective Study. Internal Medicine, 2023, 62, 2321-2328.   | 0.7 | 1         |
| 588 | Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. BMJ, The, 0, , e074521.  | 6.0 | 2         |
| 589 | Vaccine effectiveness against delta and omicron variants of SARS-CoV-2. BMJ, The, 0, , p1111.  | 6.0 | 2         |
| 590 | SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Frontiers in Immunology, 0, 14, .   | 4.8 | 22        |
| 591 | Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England. PLoS Biology, 2023, 21, e3002118.  | 5.6 | 6         |
| 592 | Assessment of the Risk and Symptoms of SARS-CoV-2 Infection Among Healthcare Workers During the Omicron Transmission Period: A Multicentric Study from Four Hospitals of Mainland China. Infection and Drug Resistance, 0, Volume 16, 3315-3328. | 2.7 | 0         |
| 594 | Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes. Journal of Medical Virology, 2023, 95, .   | 5.0 | 3         |
| 595 | Forecast for peak infections in the second wave of the Omicron after the adjustment of zero-COVID policy in the mainland of China. Infectious Disease Modelling, 2023, 8, 562-573.   | 1.9 | 0         |
| 596 | Clinical Characteristics, Outcomes, and Risk Factors of Patients Hospitalized for COVID-19 across the Latest Pandemic Waves: Has Something Changed?. BioMed, 2023, 3, 272-281.   | 1.1 | 1         |
| 597 | Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study. Cancers, 2023, 15, 2993.   | 3.7 | 3         |
| 598 | National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative. Journal of Infectious Diseases, 0, , .  | 4.0 | 1         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 601 | Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020â€“2022. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 1972-1978.   | 1.8  | 6         |
| 602 | A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China. <i>Emerging Microbes and Infections</i> , 2023, 12, .   | 6.5  | 10        |
| 604 | Is Omicron really mild? â€“ Comparative analysis of comorbidities and disease outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants. <i>Indian Journal of Medical Microbiology</i> , 2023, 45, 100391.                                  | 0.8  | 3         |
| 605 | Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12â€“17 years: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .   | 3.3  | 3         |
| 606 | Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study. <i>HemaSphere</i> , 2023, 7, e905.   | 2.7  | 0         |
| 607 | Comparative spatial transcriptomic profiling of severe acute respiratory syndrome coronavirus 2 Delta and Omicron variants infections in the lungs of cynomolgus macaques. <i>Journal of Medical Virology</i> , 2023, 95, .  | 5.0  | 2         |
| 608 | An exploration of the relationship between wastewater viral signals and COVID-19 hospitalizations in Ottawa, Canada. <i>Infectious Disease Modelling</i> , 2023, 8, 617-631.   | 1.9  | 1         |
| 610 | Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies. <i>Frontiers in Public Health</i> , 0, 11, .  | 2.7  | 9         |
| 611 | Mild SARS-CoV-2 infection results in long-lasting microbiota instability. <i>MBio</i> , 0, , .   | 4.1  | 2         |
| 612 | The COVID-19 pandemic in China: from dynamic zero-COVID to current policy. <i>Herz</i> , 2023, 48, 226-228.  | 1.1  | 6         |
| 613 | Exploratory analysis of SARS-CoV-2 omicron variant and its subvariant propagation: global predominance of BA.1*, BA.2*, BA.5*, BE.1*, and BQ.1*. <i>Proceedings of the Indian National Science Academy</i> , 2023, 89, 664-672.  | 1.4  | 1         |
| 614 | Critical national response in coping with Omicron variant in China, Israel, South Africa, and the United States. <i>Frontiers in Public Health</i> , 0, 11, .  | 2.7  | 0         |
| 615 | Multidimensional analysis of immune cells from COVID-19 patients identified cell subsets associated with the severity at hospital admission. <i>PLoS Pathogens</i> , 2023, 19, e1011432.   | 4.7  | 5         |
| 616 | Risk Factors Related to Severity in COVID-19 Patients: A Real-world Retrospective Cohort Study. <i>Internal Medicine</i> , 2023, , .   | 0.7  | 0         |
| 618 | Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age. <i>Journal of Korean Medical Science</i> , 2023, 38, .                 | 2.5  | 1         |
| 619 | Fitness, growth and transmissibility of SARS-CoV-2 genetic variants. <i>Nature Reviews Genetics</i> , 2023, 24, 724-734.   | 16.3 | 12        |
| 620 | Waves of inequality: income differences in intensive care due to Covid-19 in Sweden. <i>European Journal of Public Health</i> , 0, , .   | 0.3  | 0         |
| 621 | Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission. <i>Clinical Microbiology and Infection</i> , 2023, 29, 1328-1333. | 6.0  | 5         |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 640 | COVID-19 vaccination campaigns and health outcomes in Spain during 2021. <i>Applied Economics</i> , 0, , 1-14.  | 2.2  | 0         |
| 641 | Convalescent plasma for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2024, .   | 2.8  | 3         |
| 642 | COVID-19, Myocarditis and Pericarditis. <i>Circulation Research</i> , 2023, 132, 1302-1319.   | 4.5  | 35        |
| 643 | COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes. A multicontinental cohort study. <i>Journal of Medical Virology</i> , 2023, 95, . | 5.0  | 5         |
| 644 | A lung-specific mutational signature enables inference of viral and bacterial respiratory niche. <i>Microbial Genomics</i> , 2023, 9, .   | 2.0  | 3         |
| 645 | Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study. <i>Scientific Reports</i> , 2023, 13, .                    | 3.3  | 1         |
| 647 | CULTURAL PROPERTIES OF THE SOUTH AFRICAN VARIANT OFOMICRON VIRUS SARS-CoV-2 OF CORONAVIRUS INFECTION COVID-19. , 2023, 1, 36-43.  |      | 0         |
| 648 | Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. <i>Journal of Infection</i> , 2023, 87, 128-135.   | 3.3  | 8         |
| 649 | Rapid review and meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants. <i>BMC Infectious Diseases</i> , 2023, 23, .  | 2.9  | 7         |
| 650 | Unpacking the Complexity of COVID-19 Fatalities: Adverse Events as Contributing Factorsâ€”A Single-Center, Retrospective Analysis of the First Two Years of the Pandemic. <i>Viruses</i> , 2023, 15, 1430.    | 3.3  | 0         |
| 651 | Does tourism affect the long term course of COVID-19 pandemic in a country of destination? Evidence from a popular Greek island in 2020 where control measures were implemented. , 0, 3, .                    |      | 0         |
| 652 | COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022. <i>Eurosurveillance</i> , 2023, 28, .   | 7.0  | 0         |
| 653 | Immunological Characteristics of Unvaccinated Patients with COVID-19 in the Early Pandemic Period. <i>Laboratory Medicine Online</i> , 2023, 13, 212-222.   | 0.2  | 0         |
| 655 | Hospital admissions linked to SARS-CoV-2 infection in children and adolescents: cohort study of 3.2 million first ascertained infections in England. <i>BMJ, The</i> , 0, , e073639.                          | 6.0  | 6         |
| 656 | High prevalence of persistent COVID-19-related health anxiety and social restriction in patients with haematological disorders. <i>British Journal of Haematology</i> , 2023, 202, 1065-1070.                 | 2.5  | 0         |
| 657 | Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis. <i>JAMA Network Open</i> , 2023, 6, e2321985.   | 5.9  | 1         |
| 658 | SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. <i>Nature Medicine</i> , 2023, 29, 1760-1774.                              | 30.7 | 27        |
| 659 | Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis. <i>BMJ Global Health</i> , 2023, 8, e012328.       | 4.7  | 14        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 660 | T-Cell Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Measured by an Interferon- $\gamma$ Release Assay Is Strongly Associated With Patient Outcomes in Vaccinated Persons Hospitalized With Delta or Omicron Variants. <i>Journal of Infectious Diseases</i> , 0, , . | 4.0  | 1         |
| 661 | COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73â€–608 Patients With Cancer and 621â€–475 Matched Controls in Singapore. <i>JAMA Oncology</i> , 2023, 9, 1221.   | 7.1  | 4         |
| 662 | Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination. <i>Nature Communications</i> , 2023, 14, .  | 12.8 | 2         |
| 663 | Coronavirus disease (COVID-19) in patients with hematologic malignancy. , 0, , .   |      | 0         |
| 665 | Longitudinal Association of COVID-19 Hospitalization and Death with Online Search for Loss of Smell or Taste. <i>Emerging Infectious Diseases</i> , 2023, 29, .  | 4.3  | 1         |
| 666 | Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. <i>Nature Communications</i> , 2023, 14, .  | 12.8 | 5         |
| 668 | In Support of Universal Admission Testing for SARS-CoV-2 During Significant Community Transmission. <i>Clinical Infectious Diseases</i> , 2024, 78, 439-444.   | 5.8  | 0         |
| 670 | Pre-Operative SARS-CoV-2 Testing in Asymptomatic Heart Transplantation Recipients. <i>Biomedicines</i> , 2023, 11, 2103.   | 3.2  | 0         |
| 671 | A Pictorial Essay Describing the CT Imaging Features of COVID-19 Cases throughout the Pandemic with a Special Focus on Lung Manifestations and Extrapulmonary Vascular Abdominal Complications. <i>Biomedicines</i> , 2023, 11, 2113.  | 3.2  | 3         |
| 672 | A multi-institutional study of short-term mortality in COVID-positive patients undergoing hip fracture surgery: is survival better than expected?. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 0, , .  | 1.4  | 0         |
| 673 | Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains. <i>Immunobiology</i> , 2023, 228, 152720.   | 1.9  | 1         |
| 674 | Antiviral Effect of Candies Containing Persimmon-Derived Tannin against SARS-CoV-2 Delta Strain. <i>Viruses</i> , 2023, 15, 1636.  | 3.3  | 1         |
| 675 | Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern. <i>MBio</i> , 0, , .  | 4.1  | 2         |
| 679 | Comparison of two COVID-19 mortality measures used during the pandemic response in England. <i>International Journal of Epidemiology</i> , 2024, 53, .   | 1.9  | 0         |
| 680 | Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination. <i>Vaccines</i> , 2023, 11, 1342.  | 4.4  | 0         |
| 681 | Characterization of mild or asymptomatic patient admitted with Omicron variant of COVID-19 infection in Tibetan mobile cabin hospital China, Augustâ€–October 2022. <i>Frontiers in Public Health</i> , 0, 11, .   | 2.7  | 0         |
| 682 | Predicting the public health impact of bivalent vaccines and nirmatrelvir-ritonavir against COVID-19. <i>Open Forum Infectious Diseases</i> , 0, , .   | 0.9  | 0         |
| 683 | Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types. <i>Journal of the Royal Society Interface</i> , 2023, 20, .   | 3.4  | 3         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 684 | Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk. <i>Journal of Infectious Diseases</i> , 2023, 228, 1667-1674.                                | 4.0  | 5         |
| 686 | Inequalities in COVID-19 severe morbidity and mortality by country of birth in Sweden. <i>Nature Communications</i> , 2023, 14, .   | 12.8 | 2         |
| 687 | Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. <i>EClinicalMedicine</i> , 2023, 63, 102154.                                    | 7.1  | 21        |
| 688 | Hospitalization Among Patients Treated With Molnupiravir: A Retrospective Study of Administrative Data. <i>Clinical Therapeutics</i> , 2023, , .  | 2.5  | 0         |
| 689 | Hospital overcrowding caused by covid-19 and chronic kidney disease mortality. <i>Journal of Diabetes, Metabolic Disorders &amp; Control</i> , 2023, 10, 66-73.   | 0.1  | 0         |
| 690 | Vaccination and Outcomes in Critically Ill Patients With COVID-19: A Nuanced But Encouraging Story*. <i>Critical Care Medicine</i> , 2023, 51, 1272-1275.   | 0.9  | 0         |
| 691 | A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022. <i>Eurosurveillance</i> , 2023, 28, .                                     | 7.0  | 0         |
| 692 | Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases. <i>Rheumatology</i> , 0, , .   | 1.9  | 4         |
| 693 | Clinical characteristics and outcomes of COVID-19 patients with varying renal functions statuses during the Omicron pandemic in Shanghai. <i>BMC Nephrology</i> , 2023, 24, .   | 1.8  | 0         |
| 694 | Mortality associated with Omicron and influenza infections in France before and during the COVID-19 pandemic. <i>Epidemiology and Infection</i> , 0, , 1-22.  | 2.1  | 1         |
| 695 | Genetic signature detected in TÂcell receptors from patients with severe COVID-19. <i>IScience</i> , 2023, 26, 107735.  | 4.1  | 1         |
| 696 | Prognostic factors for the outcomes of COVID-19 patients infected with SARS-CoV-2 Omicron and Delta variants. <i>BMC Medical Genomics</i> , 2023, 16, .   | 1.5  | 1         |
| 697 | Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review. <i>Vaccines</i> , 2023, 11, 1502.   | 4.4  | 3         |
| 698 | SARS-CoV-2 nonstructural protein 6 from Alpha to Omicron: evolution of a transmembrane protein. <i>MBio</i> , 0, , .  | 4.1  | 1         |
| 699 | Impact of Age and Variant Time Period on Clinical Presentation and Outcomes of Hospitalized Coronavirus Disease 2019 Patients. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2023, 7, 411-429. | 2.4  | 0         |
| 700 | Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study. <i>Scientific Reports</i> , 2023, 13, .   | 3.3  | 1         |
| 701 | SARSâ€CoVâ€2 infection in children with cystic fibrosis: A crossâ€sectional multicenter study in Spain. New waves, new knowledge. <i>Pediatric Pulmonology</i> , 2023, 58, 3195-3205.                                 | 2.0  | 0         |
| 702 | Pediatric Hospitalizations and ICU Admissions Due to COVID-19 and Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 in England. <i>JAMA Pediatrics</i> , 2023, 177, 947.              | 6.2  | 7         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 703 | Clinical Severity of SARS-CoV-2 Variants during COVID-19 Vaccination: A Systematic Review and Meta-Analysis. <i>Viruses</i> , 2023, 15, 1994.   | 3.3  | 2         |
| 704 | Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients. <i>Leukemia and Lymphoma</i> , 2023, 64, 1981-1991.   | 1.3  | 1         |
| 705 | THE ROLE OF THE MATHEMATICAL SCIENCES IN SUPPORTING THE COVID-19 RESPONSE IN AUSTRALIA AND NEW ZEALAND. <i>ANZIAM Journal</i> , 2022, 64, 315-337.  | 0.2  | 5         |
| 706 | Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era. <i>Annals of Hematology</i> , 2023, 102, 2707-2716.   | 1.8  | 1         |
| 707 | Metasurface-Driven and Nanomaterial-Coupled Plasmonic Biosensor for the Rapid and Quantitative Clinical Identification of Neutralizing Antibodies against SARS-CoV-2 Variants. <i>Advanced Functional Materials</i> , 2023, 33, .   | 14.9 | 0         |
| 708 | Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSVMT) in golden syrian hamster. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4856-4874.  | 12.0 | 0         |
| 709 | Sleep disorders after COVID-19 in Czech population: Post-lockdown national online survey. <i>Sleep Medicine: X</i> , 2023, 6, 100087.   | 1.5  | 1         |
| 710 | Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020-2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality. <i>BMC Infectious Diseases</i> , 2023, 23, . | 2.9  | 1         |
| 711 | COVID-19 Outcomes in Kidney Transplant Recipients in a German Transplant Center. <i>Journal of Clinical Medicine</i> , 2023, 12, 6103.  | 2.4  | 0         |
| 712 | Higher in-hospital mortality in SARS-CoV-2 omicron variant infection compared to influenza infection-Insights from the CORONA Germany study. <i>PLoS ONE</i> , 2023, 18, e0292017.  | 2.5  | 2         |
| 713 | Outcomes and characteristics of patients hospitalized for COVID-19 in British Columbia, Ontario and Quebec during the Omicron wave. <i>CMAJ Open</i> , 2023, 11, E672-E683.   | 2.4  | 2         |
| 714 | SARS-CoV-2 variants evolve convergent strategies to remodel the host response. <i>Cell</i> , 2023, 186, 4597-4614.e26.  | 28.9 | 13        |
| 715 | Comparative Evaluation of the Clinical Severity of COVID-19 of Vaccinated and Unvaccinated Patients in Southeastern Romania in the First 6 Months of 2022, during the Omicron Wave. <i>Healthcare (Switzerland)</i> , 2023, 11, 2184.   | 2.0  | 1         |
| 717 | Persisting symptoms common but inability to work rare: a one-year follow-up study of Finnish hospitalised COVID-19 patients. <i>Infectious Diseases</i> , 2023, 55, 821-830.  | 2.8  | 0         |
| 718 | Interferon $\beta$ -1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trial. <i>EclinicalMedicine</i> , 2023, 62, 102082.   | 7.1  | 0         |
| 720 | The COVID-19 pandemic in Greenland, epidemic features and impact of early strict measures, March 2020 to June 2022. <i>Eurosurveillance</i> , 2023, 28, .   | 7.0  | 1         |
| 721 | Ecological and Evolutionary Insights About Emerging Infectious Diseases from the COVID-19 Pandemic. <i>Annual Review of Ecology, Evolution, and Systematics</i> , 2023, 54, .   | 8.3  | 2         |
| 722 | An age-cohort simulation model for generating COVID-19 scenarios: A study from Ireland's pandemic response. <i>European Journal of Operational Research</i> , 2024, 313, 343-358.   | 5.7  | 1         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 723 | The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. <i>EBioMedicine</i> , 2023, 95, 104753.  | 6.1  | 8         |
| 726 | Comparative analysis of characteristics and outcomes in hospitalized COVID-19 patients infected with different SARS-CoV-2 variants between January 2020 and April 2022 – A retrospective single-center cohort study. <i>Journal of Infection and Public Health</i> , 2023, 16, 1806-1812. | 4.1  | 0         |
| 727 | Mitochondrial mass of circulating NK cells as a novel biomarker in severe SARS-CoV-2 infection. <i>International Immunopharmacology</i> , 2023, 124, 110839.  | 3.8  | 1         |
| 728 | Is molnupiravir a wise investment? Reassessing COVID-19 treatment strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 2779-2780.   | 3.0  | 2         |
| 729 | Antiviral therapy of coronavirus disease 2019 (COVID-19). <i>Journal of the Formosan Medical Association</i> , 2023, , .  | 1.7  | 1         |
| 731 | A Cross-sectional Study of Clinical Characteristics and Outcomes among Adults with Laboratory-confirmed SARS-CoV-2 Infection with Omicron Variant. <i>Journal of Pure and Applied Microbiology</i> , 2023, 17, 1814-1823.   | 0.9  | 0         |
| 732 | Lower gut abundance of <i>Eubacterium rectale</i> is linked to COVID-19 mortality. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .   | 3.9  | 0         |
| 734 | COVID-19-related excess mortality – an overview of the current evidence. <i>Archiwum Medycyny Sadowej I Kryminologii</i> , 2023, 73, 33-44.   | 0.3  | 0         |
| 735 | A standardised protocol for relative SARS-CoV-2 variant severity assessment, applied to Omicron BA.1 and Delta in six European countries, October 2021 to February 2022. <i>Eurosurveillance</i> , 2023, 28, .  | 7.0  | 1         |
| 736 | Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants. <i>Molecular Therapy</i> , 2023, , .  | 8.2  | 0         |
| 738 | Patients Hospitalized for COVID-19 in the Periods of Delta and Omicron Variant Dominance in Greece: Determinants of Severity and Mortality. <i>Journal of Clinical Medicine</i> , 2023, 12, 5904.   | 2.4  | 0         |
| 739 | The clinical characteristics of COVID-19 omicron variant infection in pregnant women and their neonates. <i>Frontiers in Medicine</i> , 0, 10, .  | 2.6  | 1         |
| 740 | Estimate of COVID-19 Deaths, China, December 2022–February 2023. <i>Emerging Infectious Diseases</i> , 2023, 29, .  | 4.3  | 5         |
| 741 | A chronological review of COVID-19 case fatality rate and its secular trend and investigation of all-cause mortality and hospitalization during the Delta and Omicron waves in the United States: a retrospective cohort study. <i>Frontiers in Public Health</i> , 0, 11, .              | 2.7  | 1         |
| 742 | Ancestral, Delta, and Omicron (BA.1) SARS-CoV-2 strains are dependent on serine proteases for entry throughout the human respiratory tract. <i>Med</i> , 2023, , .  | 4.4  | 0         |
| 743 | Have clinical studies on COVID-19 matured?. <i>Respiratory Investigation</i> , 2023, 61, 800-801.   | 1.8  | 0         |
| 744 | Overcoming COVID-19 vaccine hesitancy hurdles. <i>Lancet, The</i> , 2023, 402, 1129-1130.   | 13.7 | 0         |
| 745 | The impact of multiple population-wide testing and social distancing on the transmission of an infectious disease. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2023, 630, 129243.  | 2.6  | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 747 | Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study. <i>BMC Infectious Diseases</i> , 2023, 23, .   | 2.9 | 0         |
| 750 | Understanding the Omicron Variant in the COVID-19 Pandemic. , 0, , .  |     | 0         |
| 751 | Post COVID sequelae among COVID-19 survivors: insights from the Indian National Clinical Registry for COVID-19. <i>BMJ Global Health</i> , 2023, 8, e012245.  | 4.7 | 0         |
| 752 | Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure. <i>British Journal of Pharmacology</i> , 2024, 181, 345-361.   | 5.4 | 2         |
| 753 | Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis. <i>Health Technology Assessment</i> , 0, , 1-92.  | 2.8 | 0         |
| 754 | EuCARE-hospitalised study protocol: a cohort study of patients hospitalised with COVID-19 in the EuCARE project. <i>BMC Infectious Diseases</i> , 2023, 23, .   | 2.9 | 1         |
| 755 | Evolving impact of the COVID-19 pandemic on lung transplant recipients: A single-center experience. <i>Journal of Heart and Lung Transplantation</i> , 2024, 43, 442-452.   | 0.6 | 0         |
| 756 | Database derived from an electronic medical record-based surveillance network of US emergency department patients with acute respiratory illness. <i>BMC Medical Informatics and Decision Making</i> , 2023, 23, .  | 3.0 | 0         |
| 757 | Difference of Clinical Characteristics in Patients with Omicron and Delta Variants of SARS-CoV-2 in Beijing, China. <i>Infectious Diseases &amp; Immunity</i> , 2023, 3, 75-82.   | 0.6 | 0         |
| 758 | Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 1178-1186.   | 3.1 | 1         |
| 759 | Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings. <i>International Journal of Infectious Diseases</i> , 2023, 137, 98-110.   | 3.3 | 4         |
| 760 | Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-coronavirus disease policy in China: A prospective, observational study. <i>American Journal of Transplantation</i> , 2024, 24, 631-640. | 4.7 | 0         |
| 761 | Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .  | 3.9 | 2         |
| 762 | Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients. <i>Journal of Hepatology</i> , 2024, 80, 109-123.   | 3.7 | 1         |
| 764 | Humoral and cellular immunity against diverse SARS-CoV-2 variants. <i>Journal of Genetics and Genomics</i> , 2023, 50, 934-947.   | 3.9 | 1         |
| 765 | Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational study. <i>EBioMedicine</i> , 2023, 97, 104843.   | 6.1 | 1         |
| 766 | Infection prevention measures for patients on hemodialysis during COVID-19 pandemic in Japan: a nationwide questionnaire follow-up survey in 2022. <i>Renal Replacement Therapy</i> , 2023, 9, .  | 0.7 | 0         |
| 767 | Viral codon optimization on SARS-CoV-2 Spike boosts immunity in the development of COVID-19 mRNA vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .   | 5.0 | 1         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 768 | Impact of mRNA-based vaccines in the prevention of adverse outcomes of COVID-19 infection in pregnancy: a single-center cohort study. <i>Frontiers in Pediatrics</i> , 0, 11, .  | 1.9  | 0         |
| 769 | Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. <i>Viruses</i> , 2023, 15, 2153.   | 3.3  | 2         |
| 770 | Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient. <i>Virology Journal</i> , 2023, 20, .   | 3.4  | 1         |
| 771 | Anti-SARS-CoV-2 antibody levels predict outcome in COVID-19 patients with type 2 diabetes: a prospective cohort study. <i>Scientific Reports</i> , 2023, 13, .   | 3.3  | 1         |
| 772 | Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England. <i>Lancet Regional Health - Europe</i> , The, 2023, 35, 100755. | 5.6  | 4         |
| 773 | Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service. <i>BMC Infectious Diseases</i> , 2023, 23, .   | 2.9  | 1         |
| 774 | Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era. <i>Infectious Diseases</i> , 2024, 56, 116-127.   | 2.8  | 0         |
| 775 | Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study. <i>Frontiers in Pharmacology</i> , 0, 14, .   | 3.5  | 0         |
| 776 | Reproduction number projection for the COVID-19 pandemic. , 2023, 2023, .  |      | 0         |
| 777 | Blood-derived product therapies for SARS-CoV-2 infection and long COVID. <i>MedComm</i> , 2023, 4, .   | 7.2  | 0         |
| 778 | Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2023, 11, 1684.                                 | 4.4  | 0         |
| 779 | Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR therapy. <i>Cancer Medicine</i> , 2023, 12, 20838-20846.   | 2.8  | 0         |
| 780 | Outcomes of SARS-CoV-2 Omicron Variant Infections Compared With Seasonal Influenza and Respiratory Syncytial Virus Infections in Adults Attending the Emergency Department: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 0, , .   | 5.8  | 4         |
| 781 | Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023. <i>Frontiers in Public Health</i> , 0, 11, .  | 2.7  | 0         |
| 782 | Timely and Equitably Allocation of Medical Resources Considering Secondary Mortality Under Public Health Emergency. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4  | 0         |
| 783 | SARS-CoV-2 genomics and impact on clinical care for COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, ii25-ii36.  | 3.0  | 1         |
| 784 | Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia. <i>Scientific Reports</i> , 2023, 13, .   | 3.3  | 0         |
| 785 | The neurobiology of SARS-CoV-2 infection. <i>Nature Reviews Neuroscience</i> , 2024, 25, 30-42.  | 10.2 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 786 | Changing impact of COVID-19 on life expectancy 2019â€“2023 and its decomposition: Findings from 27 countries. <i>SSM - Population Health</i> , 2024, 25, 101568.   | 2.7 | 1         |
| 787 | Characteristics of hematological parameters on admission in COVID-19 Omicron variant infected in Chinese population: a large-scale retrospective study. <i>BMC Infectious Diseases</i> , 2023, 23, .                     | 2.9 | 0         |
| 789 | Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines. <i>Cell Reports</i> , 2023, 42, 113292.  | 6.4 | 1         |
| 790 | COVID myocarditis: a review of the literature. <i>Monaldi Archives for Chest Disease</i> , 0, , .  | 0.6 | 2         |
| 791 | Nosocomial SARS-CoV-2 Infections and Mortality During Unique COVID-19 Epidemic Waves. <i>JAMA Network Open</i> , 2023, 6, e2341936.  | 5.9 | 2         |
| 792 | The COVIDTW2 study: Role of COVID-19 vaccination in intubated patients with COVID-19-related acute respiratory distress syndrome in Taiwan. <i>Journal of Infection and Chemotherapy</i> , 2023, , .                     | 1.7 | 0         |
| 793 | Clinical features and outcomes in adults with COVID-19 during the pre-Omicron and Omicron waves. <i>Infectious Diseases Now</i> , 2024, 54, 104833.  | 1.6 | 1         |
| 794 | Incremental benefit of booster vaccinations for COVID-19 in the United Kingdom. <i>Lancet Regional Health - Europe, The</i> , 2023, 35, 100790.  | 5.6 | 0         |
| 795 | Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53. <i>Cell Reports</i> , 2023, 42, 113478.   | 6.4 | 0         |
| 796 | Vaccination, immunity, and the changing impact of COVID-19 on infant health. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .                                       | 7.1 | 4         |
| 797 | Substitution spectra of SARS-CoV-2 genome from Pakistan reveals insights into the evolution of variants across the pandemic. <i>Scientific Reports</i> , 2023, 13, .   | 3.3 | 0         |
| 798 | Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era. <i>Cancer Medicine</i> , 2023, 12, 21148-21158.                  | 2.8 | 0         |
| 799 | SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain. <i>Transplantation</i> , 0, , .                     | 1.0 | 0         |
| 800 | Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial. <i>Virology Journal</i> , 2023, 20, .             | 3.4 | 1         |
| 801 | Incidence and outcome of hospital-acquired COVID-19 infections in secondary and tertiary care hospitals in the era of COVID-19 vaccinations. <i>Antimicrobial Stewardship &amp; Healthcare Epidemiology</i> , 2023, 3, . | 0.5 | 0         |
| 802 | Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B. <i>BMC Infectious Diseases</i> , 2023, 23, .                                      | 2.9 | 0         |
| 803 | Clinical characteristics and high risk factors of patients with Omicron variant strain infection in Hebei, China. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .                                     | 3.9 | 0         |
| 804 | The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study. <i>Vaccine</i> , 2024, 42, 53-58.   | 3.8 | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 805 | Omicron induced distinct immune respiratory transcriptomics signatures compared to pre-existing variants in critically ill COVID-19 patients. <i>Journal of Medical Virology</i> , 2023, 95, .  | 5.0  | 0         |
| 806 | Characteristics and outcomes of patients hospitalized for infection with influenza, SARS-CoV-2 or respiratory syncytial virus in the season 2022/2023 in a large German primary care centre. <i>European Journal of Medical Research</i> , 2023, 28, .  | 2.2  | 1         |
| 807 | A multinational case series describing successful treatment of persistent SARS-CoV-2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir/ritonavir.. <i>Open Forum Infectious Diseases</i> , 0, , .  | 0.9  | 0         |
| 808 | Antibody responses to SARS-CoV-2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort study. <i>Journal of Medical Virology</i> , 2023, 95, .   | 5.0  | 0         |
| 809 | Anti-SARS-CoV-2 Antibody Testing: Role and Indications. <i>Journal of Clinical Medicine</i> , 2023, 12, 7575.   | 2.4  | 1         |
| 810 | Prognosis of hospitalized patients during different pandemic waves in Greece: Omicron innocent until proven guilty?. <i>European Journal of Internal Medicine</i> , 2024, 121, 139-142.   | 2.2  | 0         |
| 811 | Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19 vaccination: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2024, 154, 1394-1412.   | 5.1  | 0         |
| 812 | Impact of Surge Strain and Pandemic Progression on Prognostication by an Established COVID-19-Specific Severity Score. , 2023, 5, e1021.  |      | 0         |
| 813 | Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups. <i>Microbiology Spectrum</i> , 2023, 11, .   | 3.0  | 1         |
| 814 | Exploring the relationship between SARS-CoV-2 variants, illness severity at presentation, in-hospital mortality and COVID-19 vaccination in a low middle-income country: A retrospective cross-sectional study. <i>Health Science Reports</i> , 2023, 6, .  | 1.5  | 1         |
| 815 | Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022. <i>Eurosurveillance</i> , 2023, 28, . | 7.0  | 0         |
| 816 | High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1. <i>Journal of Virology</i> , 0, , .  | 3.4  | 0         |
| 817 | Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study. <i>Annals of Hematology</i> , 2024, 103, 981-992.  | 1.8  | 1         |
| 819 | Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract. <i>EBioMedicine</i> , 2024, 99, 104916.   | 6.1  | 1         |
| 820 | Health Care Resource Utilization and Costs Associated With COVID-19 Among Pediatrics Managed in the Community or Hospital Setting in England: A Population-based Cohort Study. <i>Pediatric Infectious Disease Journal</i> , 2024, 43, 209-216.   | 2.0  | 0         |
| 821 | Clinical course and management of COVID-19 in the era of widespread population immunity. <i>Nature Reviews Microbiology</i> , 2024, 22, 75-88.  | 28.6 | 1         |
| 822 | Airway and Systemic Immune Responses Following the Third COVID-19 Vaccination in COPD Patients. <i>International Journal of COPD</i> , 0, Volume 18, 3027-3036.   | 2.3  | 0         |
| 823 | Comparison of the incidence of severe outcomes in outpatients with COVID-19 or seasonal influenza without risk factors: retrospective analysis of a health insurance claims-database. <i>Journal of Clinical Virology Plus</i> , 2023, , 100175.  | 1.0  | 0         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 824 | Factors associated with prolonged viral shedding of SARS-CoV-2 Omicron variant infection in Shanghai: A multicenter, retrospective, observational study. <i>Journal of Medical Virology</i> , 2023, 95, .  | 5.0  | 1         |
| 825 | Sensecor: A framework for COVID-19 variants severity classification and symptoms detection. <i>Evolving Systems</i> , 0, , .   | 3.9  | 0         |
| 826 | COVID-19 in Patients with Melanoma: A Single-Institution Study. <i>Cancers</i> , 2024, 16, 96.   | 3.7  | 0         |
| 827 | Changes in the intrinsic severity of severe acute respiratory syndrome coronavirus 2 according to the emerging variant: a nationwide study from February 2020 to June 2022, including comparison with vaccinated populations. <i>BMC Infectious Diseases</i> , 2024, 24, . | 2.9  | 0         |
| 828 | Analysis of the Economic Burden of COVID-19 on the Workers of a Teaching Hospital in the Centre of Italy: Changes in Productivity Loss and Healthcare Costs Pre and Post Vaccination Campaign. <i>Vaccines</i> , 2023, 11, 1791.   | 4.4  | 0         |
| 829 | Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1353.  | 4.1  | 0         |
| 831 | Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. <i>Lancet Respiratory Medicine</i> , the, 2024, 12, 207-216.  | 10.7 | 2         |
| 832 | The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double-blind, placebo-controlled dietary study. <i>BMC Nutrition</i> , 2024, 10, .  | 1.6  | 0         |
| 833 | Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants. , 2024, , 166-193.   |      | 0         |
| 834 | COVID-19 Antibody Levels among Various Vaccination Groups, One-Year Antibody Follow-Up in Two University Hospitals from Western and Central Turkey. <i>Vaccines</i> , 2024, 12, 59.  | 4.4  | 0         |
| 835 | Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021â€“2022. <i>Vaccines</i> , 2024, 12, 58.  | 4.4  | 0         |
| 836 | SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir. <i>Microbiology Spectrum</i> , 2024, 12, .  | 3.0  | 0         |
| 837 | Fluctuation in SARS-CoV-2 Environmental Surface Contamination Levels in Homes Where Patients With COVID-19 Stayed for Recuperation. <i>Cureus</i> , 2024, , .  | 0.5  | 1         |
| 839 | Comparative analysis of Covid-19 course and post-covid syndrome caused by early strains and omicron strain in patients with rheumatic diseases. <i>Medical Alphabet</i> , 2024, , 31-38.   | 0.2  | 0         |
| 840 | Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis. <i>BMC Public Health</i> , 2024, 24, .   | 2.9  | 0         |
| 841 | A maintenance hemodialysis patient complicated with hypogammaglobulinemia presenting typical COVID-19 pneumonia CT findings: a case report. <i>Renal Replacement Therapy</i> , 2024, 10, .   | 0.7  | 0         |
| 842 | COVID-19 and outcomes in Chinese peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2024, 44, 117-124.   | 2.3  | 0         |
| 843 | Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020â€“2023): a multicentre prospective cohort study. , 2024, 22, 100348.   |      | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 844 | The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2. ACS Omega, 2024, 9, 5175-5192.   | 3.5 | 0         |
| 845 | A prospective cohort study of SARS-CoV-2 infection-induced seroconversion and disease incidence in German healthcare workers before and during the rollout of COVID-19 vaccines. PLoS ONE, 2024, 19, e0294025.  | 2.5 | 0         |
| 846 | Significance of Persistent Systemic Support in the Clinical Course of Delayed Post-hypoxic Leukoencephalopathy Following Severe Coronavirus Disease 2019. Internal Medicine, 2024, 63, 1167-1172.   | 0.7 | 0         |
| 847 | The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis. Human Vaccines and Immunotherapeutics, 2024, 20, .   | 3.3 | 1         |
| 848 | The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study. Vaccine, 2024, 42, 1383-1391.  | 3.8 | 0         |
| 849 | Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil. Open Forum Infectious Diseases, 2024, 11, .  | 0.9 | 0         |
| 850 | The Impact of Clinical Factors and SARS-CoV-2 Variants on Antibody Production in Vaccinated German Healthcare Professionals Infected Either with the Delta or the Omicron Variant. Vaccines, 2024, 12, 163.   | 4.4 | 0         |
| 851 | Genetic characteristics of SARS-CoV-2 virus variants observed upon three waves of the COVID-19 pandemic in Ukraine between February 2021â€“January 2022. Heliyon, 2024, 10, e25618.   | 3.2 | 0         |
| 852 | Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits. Scientific Reports, 2024, 14, .  | 3.3 | 0         |
| 853 | Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19. JAMA Network Open, 2024, 7, e2354991.  | 5.9 | 0         |
| 854 | Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study. The Lancet Regional Health Americas, 2024, 31, 100693.    | 2.6 | 0         |
| 855 | Quantifying how much host, pathogen, and other factors affect human protective adaptive immune responses. Frontiers in Immunology, 0, 15, .   | 4.8 | 0         |
| 856 | Comparative analysis of symptom profile and risk of death associated with infection by SARSâ€“CoVâ€“2 and its variants in Hong Kong. Journal of Medical Virology, 2024, 96, .   | 5.0 | 0         |
| 857 | Estimating infection prevalence using the positive predictive value of self-administered rapid antigen diagnostic tests: An exploration of SARS-CoV-2 surveillance data in the Netherlands from May 2021 to April 2022. PLoS ONE, 2024, 19, e0298218. | 2.5 | 0         |
| 858 | Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review. Clinical Chemistry and Laboratory Medicine, 2024, 62, 1029-1043.   | 2.3 | 1         |
| 859 | Inequalities in regional excess mortality and life expectancy during the COVID-19 pandemic in Europe. Scientific Reports, 2024, 14, .   | 3.3 | 1         |
| 860 | Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation. Eurosurveillance, 2024, 29, .  | 7.0 | 0         |
| 861 | Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection. Frontiers in Public Health, 0, 12, .  | 2.7 | 0         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 863 | Newspaper Coverage of Hospitals During a Prolonged Health Crisis: Longitudinal Mixed Methods Study. <i>JMIR Public Health and Surveillance</i> , 0, 10, e48134.  | 2.6  | 0         |
| 864 | Altered Plasma microRNA Signature in Hospitalized COVID-19 Patients Requiring Oxygen Support. <i>Microorganisms</i> , 2024, 12, 440.   | 3.6  | 0         |
| 865 | Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study. <i>Viruses</i> , 2024, 16, 328.      | 3.3  | 0         |
| 867 | A review of the clinical characteristics and management of immunosuppressed patients living with HIV or solid organ transplants infected with SARS-CoV-2 omicron variants. <i>Frontiers in Public Health</i> , 0, 12, .        | 2.7  | 0         |
| 868 | Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada. <i>PLoS ONE</i> , 2024, 19, e0299304.    | 2.5  | 0         |
| 869 | A risk stratification model for high-flow nasal cannula use in patients with coronavirus disease 2019 in Japan: A single-center retrospective observational cohort study. <i>PLoS ONE</i> , 2024, 19, e0290937.                | 2.5  | 0         |
| 870 | Prevalence of bacteria, fungi, and virus coinfections with SARS-CoV-2 Omicron variant among patients with severe COVID-19 in Guangzhou, China, winter 2022. <i>Biosafety and Health</i> , 2024, 6, 92-97.                      | 2.7  | 0         |
| 871 | Cognition and Memory after Covid-19 in a Large Community Sample. <i>New England Journal of Medicine</i> , 2024, 390, 806-818.  | 27.0 | 0         |
| 873 | Decomposing mechanisms of COVID-19 mortality in empirical datasets: A modeling study. <i>Journal of Theoretical Biology</i> , 2024, 584, 111771.   | 1.7  | 0         |
| 874 | Investigating the Epidemiological Trend of COVID-19 Disease in Kohgiluyeh and Boyer Ahmad Province, Iran. , 2023, 28, 565-578.   |      | 0         |
| 875 | Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity. <i>Virology</i> , 2024, 594, 110050.   | 2.4  | 0         |
| 876 | An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. <i>Science Translational Medicine</i> , 2024, 16, .   | 12.4 | 0         |
| 877 | Effectiveness of the SARS-CoV-2 Vaccination in Preventing Severe Disease-Related Outcomes: A Population-Based Study in the Italian Province of Bolzano (South Tyrol). <i>International Journal of Public Health</i> , 0, 69, . | 2.3  | 0         |
| 878 | Molecular epidemiology and temporal dynamic of SARS-CoV-2 imported from Hong Kong to mainland China. , 2024, 3, 100054.  |      | 0         |
| 879 | Interaction between host G3BP and viral nucleocapsid protein regulates SARS-CoV-2 replication and pathogenicity. <i>Cell Reports</i> , 2024, 43, 113965.   | 6.4  | 0         |
| 880 | The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period. <i>Pathogens</i> , 2024, 13, 267.                                     | 2.8  | 0         |
| 881 | Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2024, 143, 107016.                                   | 3.3  | 0         |
| 882 | Update on Omicron variant and its threat to vulnerable populations. <i>Public Health in Practice</i> , 2024, 7, 100494.  | 1.5  | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 883 | Effect of Maraviroc and/or Favipiravir plus systemic steroids versus systemic steroids only on the viral load of adults with severe COVID-19: A clinical trial. F1000Research, 0, 13, 180.              | 1.6 | 0         |
| 884 | Navigating the waves in Colombia: a cohort study of inpatient care during four COVID-19 waves. Brazilian Journal of Infectious Diseases, 2024, 28, 103737.  | 0.6 | 0         |
| 885 | Efficacy of the COVID-19 vaccination in patients with asymptomatic or mild illness during the Omicron epidemic in Guangzhou: a multi-centre retrospective cohort study. Annals of Medicine, 2024, 56, . | 3.8 | 0         |
| 886 | Functional dissection of the spike glycoprotein S1 subunit and identification of cellular cofactors for regulation of swine acute diarrhea syndrome coronavirus entry. Journal of Virology, 2024, 98, . | 3.4 | 0         |
| 887 | Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service. PLoS ONE, 2024, 19, e0300306.          | 2.5 | 0         |
| 888 | A cohort study of patients hospitalised with SARS-CoV-2 infection in Ontario: patient characteristics and outcomes by wave. Swiss Medical Weekly, 2024, 154, 3636.                                      | 1.6 | 0         |
| 889 | Estimating actual SARS-CoV-2 infections from secondary data. Scientific Reports, 2024, 14, .  | 3.3 | 0         |